

Company Profile





Kemandirian Industri Farmasi Nasional

*National Pharmaceutical
Industry Independence*

Struktur Kepemilikan Saham Bio Farma Group

Bio Farma Group Stakeholder Structure



1% Lembar Saham Seri A
Negara Republik Indonesia



99% Saham Seri B PT Danantara
Asset Management (Persero)



Pemerintah 1 Saham Seri A
Dwiwarna
Bio Farma 89,82%
Publik 10,18%



Pemerintah 1 Saham Seri A
Dwiwarna
Bio Farma 80,664%
Publik 19,336%



Pemerintah 1 Saham Seri A
Dwiwarna
Bio Farma 99%



Pada awal tahun 2020, Holding Badan Usaha Milik Negara (BUMN) Farmasi resmi terbentuk. Bio Farma dipercaya untuk menjadi Induk Holding BUMN Farmasi. Pembentukan Holding BUMN Farmasi dalam rangka memberikan solusi yang lebih menyeluruh terhadap kesehatan global dan penyakit di negara berkembang, serta memperkuat kemandirian industri farmasi nasional.

Tujuan dari Holding BUMN Farmasi ini adalah selain untuk memperkuat kemandirian industri farmasi nasional, juga meningkatkan ketersediaan produk, dengan menciptakan inovasi bersama dalam penyediaan produk farmasi untuk mendukung ekosistem farmasi dimasa yang akan datang.

At the beginning of 2020, State-owned Pharmaceutical Holding was officially formed. Bio Farma is trusted to be the Parent of State-owned Pharmaceutical Holding. Establishment of State-owned Pharmaceutical holdings in order to provide more comprehensive solutions to global health and diseases in developing countries, as well as strengthen the self-reliance of national pharmaceutical industry.

The purpose of State-owned Pharmaceutical Holding is to strengthen the self-reliance of national pharmaceutical industry, and also to increase the availability of products by creating joint innovations in order to provide pharmaceutical products that support the pharmaceutical ecosystem in the future.



Penyedia *Life Science product* seperti vaksin, serum, & *blood product*.

Provision of Life Science products such as vaccines, serum & blood products.



Penyediaan obat-obatan kimia sintetis, penyediaan bahan baku obat, distribusi, ritel farmasi, klinik kesehatan dan laboratorium medis.

Provision of synthetic chemical drugs, provision of medicinal raw materials, distribution, pharmaceutical retail, health clinic, and medical laboratory.



Penyediaan obat-obatan herbal dan alat kesehatan.

Provision of medicines herbs and medical devices.



Perusahaan BUMN bergerak dalam industri yang berbasis teknologi nuklir.

State-owned company operating in an industry based on nuclear technology.

● Sejarah Bio Farma Group

Bio Farma Group History

Kementerian BUMN RI telah mensahkan secara resmi beroperasinya Holding Farmasi di awal tahun 2020, terdiri dari tiga perusahaan BUMN farmasi yaitu; **PT Bio Farma (Persero)** sebagai induk Holding, yang sahamnya masih dimiliki 100% oleh pemerintah, beranggotakan **PT Kimia Farma Tbk** dan **PT Indofarma Tbk** & pada tahun 2022 **PT INUKI** ditetapkan juga sebagai anggota Holding BUMN Farmasi. Dasar penetapan dan pengesahan Bio Farma sebagai induk Holding BUMN Farmasi, adalah dengan telah keluarnya surat persetujuan dari Menteri BUMN selaku RUPS yang menyetujui pengalihan seluruh saham seri B milik Negara Republik Indonesia pada Kimia Farma maupun Indofarma ke PT Bio Farma (Persero).

*The Ministry of State-Owned Enterprises of the Republic of Indonesia officially inaugurated the establishment of the Farmasi Holding in early 2020, comprising three state-owned pharmaceutical companies: **PT Bio Farma (Persero)** as the holding parent company, whose shares are still 100% owned by the government, with members **PT Kimia Farma Tbk** and **PT Indofarma Tbk**. In 2022, **PT INUKI** was also designated as a member of the BUMN Farmasi Holding. The basis for the appointment and approval of Bio Farma as the parent company of the BUMN Farmasi Holding is the issuance of an approval letter from the Minister of State-Owned Enterprises as the General Meeting of Shareholders, which approves the transfer of all series B shares owned by the Republic of Indonesia in Kimia Farma and Indofarma to PT Bio Farma (Persero).*

Bio Farma Group
Ultimate Goals:

Availability
Accesablility
Affordability





● Visi & Misi Bio Farma Group

Bio Farma Group Vision & Mission



Visi

Menjadi perusahaan layanan kesehatan berdaya saing global yang berkelanjutan untuk meningkatkan kualitas hidup.

Vision

To become a globally competitive and sustainable healthcare services company to improve the quality of life.

Misi

Mengembangkan, menyediakan dan memasarkan produk dan layanan kesehatan yang inovatif serta berkualitas tinggi.

Memaksimalkan efisiensi, produktivitas, dan keterjangkauan produk dan layanan kesehatan.

Memperkuat kemandirian untuk membangun ekosistem kesehatan nasional.

Memberikan nilai tambah berkelanjutan bagi seluruh *stakeholder*.

Mission

Develop, provide, and market innovative and high-quality healthcare products and services.

Maximize efficiency, productivity, and affordability of healthcare products and services.

Strengthen independence to build a national healthcare ecosystem.

Deliver sustainable added value to all stakeholders.

● Nilai dan Budaya Bio Farma Group

Bio Farma Group Value & Corporate Culture



● **Objektif Bio Farma Group**

Bio Farma Group Objectives

1.

Memperkuat kemandirian industri farmasi nasional.
Strengthen the independence of the national pharmaceutical industry.

Menurunkan impor API (Active Pharmaceutical Ingredient)
Reduce API (Active Pharmaceutical Ingredient) imports.

2.

Meningkatkan ketersediaan produk di seluruh pelosok Indonesia.
Increase the availability of products throughout Indonesia.

Meningkatkan kapabilitas & kapasitas end-to-end industri farmasi Indonesia.
Increase the end-to-end capabilities and capacity of the Indonesian pharmaceutical industry.

3.

Mengedepankan inovasi dan menyediakan produk farmasi berkualitas.
Prioritize innovation and provide quality pharmaceutical products.

Meluncurkan obat baru dan mengembangkan produk *healthcare*.
Launch new drugs and develop healthcare products.

4.

Mendukung produk farmasi bagi seluruh lapisan masyarakat.
Support pharmaceutical products for all segments of society.

Mendapatkan efisiensi biaya untuk mempertahankan keterjangkauan produk.
Achieve cost efficiency to maintain product affordability.

5.

Meningkatkan skala bisnis BUMN Farmasi.
Expand the business scale of BUMN Farmasi.

Menjadi perusahaan manufaktur farmasi No.1 di Indonesia.
Become the No.1 pharmaceutical manufacturing company in Indonesia.

6.

Memperkuat sinergi dengan sektor kesehatan nasional.
Enhance synergy with the national health sector.

Sinergi IHC menuju pembentukan Holding Sektor Kesehatan dalam jangka panjang.
Synergize IHC towards the formation of a Health Sector Holding in the long term.

● Jejak Langkah Bio Farma Group

Bio Farma Group Milestones

17 Oktober 2019

**Peraturan Pemerintah
No. 76 Tahun 2019**

tentang Penambahan
Penyertaan Modal Negara
Republik Indonesia kedalam
modal saham perusahaan
perseroan (persero) PT Bio
Farma.

**Government Regulation
No. 76 of 2019**

*on the Addition of State Capital
Participation of the Republic of
Indonesia into the share capital
of the state-owned company PT
Bio Farma.*

22 Oktober 2019

**Keputusan Menteri Keuangan Nomor 862/
KMK.06/2019**

tentang Penetapan Nilai Penambahan Penyertaan
Modal Negara Republik Indonesia kedalam Modal
Saham Perusahaan Perseroan (Persero) PT Bio
Farma.

**Decree of the Minister of Finance
Number 862/KMK.06/2019**

*on the Determination of the Value of Additional
State Capital Participation of the Republic of
Indonesia into the Share Capital of the State-
Owned Company PT Bio Farma.*

Oktober 2019

Surat Menteri BUMN:

Usulan penetapan
nilai Penambahan
Penyertaan Modal
Negara pada
PT Bio Farma (Persero).

**Minister of State-
Owned Enterprises
Letter:**

*Proposal for the
determination of the
value of the additional
state capital
participation in PT Bio
Farma (Persero).*

6 Januari 2020

**Surat Menteri BUMN Nomor: S-5/MBU/01/2020
tanggal 6 Januari 2020** tentang Persetujuan
Penerimaan Pengalihan Saham.

**Surat Menteri BUMN Nomor: S-6/MBU/01/2020
tanggal 6 Januari 2020** tentang Persetujuan
Peningkatan Modal Dasar, Penambahan Modal
Disetor serta Perubahan Anggaran Dasar Bio
Farma.

**Letter from the Minister of State-Owned
Enterprises Number: S-5/MBU/01/2020 dated
January 6, 2020** regarding Approval of the
Acceptance of Share Transfer.

**Letter from the Minister of State-Owned
Enterprises Number: S-6/MBU/01/2020 dated
January 6, 2020**
*regarding Approval of the Increase in Authorized
Capital, Additional Paid-In Capital, and
Amendments to the Articles of Association of Bio
Farma.*

31 Januari 2020

Akta Pernyataan Keputusan Pemegang Saham Perusahaan Perseroan (Persero) PT Bio Farma Nomor 38
oleh Notaris Aulia Taufani, SH.

Akta Pernyataan Perjanjian Pengalihan Saham Nomor 3
oleh Notaris Aulia Taufani, SH.

Akta Pernyataan Keputusan Pemegang Saham Perubahan Anggaran Dasar Perusahaan Perseroan (Persero) PT Bio Farma Nomor 36
oleh Notaris Aulia Taufani, SH.

Deed of Shareholders Meeting Decision of the State-Owned Company (Persero) PT Bio Farma Number 38
by Notary Aulia Taufani, SH.

Deed of Share Transfer Agreement Number 3
by Notary Aulia Taufani, SH.

Deed of Shareholders' Meeting Decision on Amendments to the Articles of Association of the State-Owned Company (Persero) PT Bio Farma Number 36
by Notary Aulia Taufani, SH.

Januari 2023

Holding BUMN Farmasi meluncurkan Logo baru yang memiliki makna bahwa Bio Farma Group senantiasa bertransformasi menjadi perusahaan yang selalu terdepan dalam bidang farmasi, dan dengan inovasi dan teknologi menjadi sebuah holding company yang kredibel dan terpercaya.

BUMN Farmasi Holding launches a new logo that signifies Bio Farma Group continuous transformation into a leading pharmaceutical company, innovating with technology to become a credible and trustworthy holding company.




Juli 2022

Holding BUMN Farmasi mendapatkan satu anggota baru yakni PT. Industri Nuklir Indonesia (Persero) atau INUKI.
INUKI akan berfokus pada produk radiofarmaka.

BUMN Farmasi Holding has added a new member, PT Industri Nuklir Indonesia (Persero) or INUKI.
INUKI will focus on radioisotope products, specifically radiopharmaceuticals.

● Struktur Bio Farma Group

Bio Farma Group Structure





2019








PT Bio Farma
(Persero)

● Siapa Kami Who We Are



Bermula dari sebuah Lembaga Riset, pada tahun 1890, kami berkembang menjadi produsen vaksin terkemuka, yang kini menjadi perusahaan *Life Science*, kami semakin berkembang dan terus melangkah maju dengan spirit “BUMN untuk Indonesia” yang terimplementasikan pada core value, “AKHLAK”.

Bio Farma merupakan BUMN produsen vaksin dan antisera yang telah mengalami perkembangan menjadi perusahaan *Life Science* dengan visi “Menjadi Perusahaan *Life Science* Kelas Dunia yang Berdaya Saing Global” dengan mengusung misi “Menyediakan dan Mengembangkan Produk *Life Science* Berstandar Internasional untuk Meningkatkan Kualitas Hidup”.

Starting from a Research Institute, in 1890, we developed into a leading vaccine manufacturer, which is now has transformed into a Life Science company, we are growing and moving forward with the spirit of “SOEs for Indonesia” implemented in the core value, “AKHLAK”.

Bio Farma is a state-owned manufacturer of Vaccines and Antisera, which has undergone development into a Life Science company with the vision “To Become a World Class Life Science Company with Global Competitiveness” and our mission is to “Provide and Develop Life Science Products of International Standards to Improving the Quality of Life”.



Kami memegang teguh filosofi, visi, misi, serta budaya kerja.

We firmly adopt the working philosophy vision, mission and the value.



Filosofi Philosophy

Mengabdikan untuk Meningkatkan Kualitas Hidup yang Lebih Baik.

Dedicated to Improving Quality of Life.

Visi Vision

Menjadi Perusahaan Life Science Kelas Dunia yang Berdaya Saing Global.

To Become a World Class Life Science Company with Global Competitiveness.

Misi Mission

Menyediakan & Mengembangkan Produk Life Science Berstandar Internasional untuk Meningkatkan Kualitas Hidup.

Provide and Develop Life Science Products of International Standards to Improving the Quality of Life.

Kebijakan Sistem Manajemen:

1. Produk Bermutu Tinggi.
2. Produk Ramah Lingkungan.
3. Berdaya Saing Global.
4. Kepuasan Pelanggan.
5. Perbaikan Berkesinambungan.
6. Perlindungan Lingkungan.
7. Pencegahan Kecelakaan dan Penyakit Akibat Kerja.
8. Penghematan Energi dan Sumber Daya Alam.
9. Melakukan Kegiatan Bisnis Perusahaan Sesuai dengan Prinsip-Prinsip Tata Kelola Perusahaan yang Baik.
10. Patuh Peraturan Perundangan dan Persyaratan Lainnya.

Corporate Policy:

1. High Quality Products.
2. Environment-Friendly Products.
3. Global Competitiveness.
4. Customer Satisfaction.
5. Continual Improvement.
6. Environmental Protection.
7. Prevention of Injury and Occupational Illness.
8. Conservation of Energy and Natural Resources.
9. Conducting Corporate Business Activities in Accordance with The Principle of Good Corporate Governance.
10. Comply with Regulations and Other Requirements.

● Budaya dan Nilai Kami *Our Heritage and Value*

Selama lebih dari 130 tahun sejak berdirinya pada 6 Agustus 1890 sebagai Lembaga Pengembangan Vaksin Negara atau Parc Vaccinogene yang berfungsi sebagai laboratorium untuk melaksanakan penelitian-penelitian beberapa penyakit menular di Hindia Belanda seperti cacar api atau *smallpox*, Bio Farma telah berkontribusi dalam meningkatkan kualitas hidup bangsa, baik di Indonesia maupun mancanegara. Saat ini berkembang menjadi perusahaan *Life Science* kelas dunia yang berdaya saing global dengan lebih dari 100 portofolio produk sejak awal pendiriannya.

For more than 130 years since its establishment on August 6, 1890, Bio Farma as a State Vaccine Development Institute or Parc Vaccinogene has functioned as a laboratory to carry out researches of several infectious diseases in the Dutch East Indies such as smallpox, Bio Farma has also contributed in improving the quality of life of the nation, both in Indonesia and abroad. It is currently developing into a world-class Life Science company that has global competitiveness with more than 100 product portfolios since its inception.





● **Fakta Singkat**
Quick Facts



AKHLAK



**INDUK HOLDING
BUMN FARMASI**

*The Holding Parent of
State-owned
Pharmaceutical*



**LIFE
SCIENCES**

3,5 Miliar
billion

Dosis per tahun
Doses per year



PQ WHO



**DIPLOMASI
KESEHATAN**
Health Diplomacy

● Jejak Langkah PT Bio Farma (Persero) *Milestone PT Bio Farma (Persero)*

06 Agustus 1890

Bio Farma berdiri dengan nama “Parc Vaccinogene” pada tanggal 6 Agustus 1890 berdasarkan Surat Keputusan Gubernur Hindia Belanda Nomor 14 tahun 1890 di Rumah Sakit Militer Weltevreden, Batavia.

Bio Farma was established under the name of “Parc Vaccinogene” on August 6, 1890 based on the Decree of the Governor of the Dutch Indies No. 14 of 1890, in the Weltevreden Military Hospital, Batavia.

1902-1941

Perubahan nama menjadi “Landskoepok Inrichting en Instituut Pasteur.” Pada tahun 1923, Bio Farma mulai menempati lokasi di Jalan Pasteur No. 28 Bandung yang dipimpin oleh L. Otten.

The Company changed its name again to “Landskoepok Inrichting en Instituut Pasteur.” In 1923, Bio Farma was relocated in Jalan Pasteur No. 28 Bandung, and led by L. Otten.

1895-1901

Pergantian nama menjadi “Parc Vaccinogene en Instituut Pasteur”.

The Company’s name was changed to “Parc Vaccinogene en Instituut Pasteur”.

1942-1945

Saat penjajahan Jepang, Bio Farma berganti nama menjadi “Bandung Boeki Kenkyushoo” yang dipimpin oleh Kikuo Kurauchi.

During the Japanese occupation, Bio Farma changed its name to “Bandung Boeki Kenkyusho” and was led by Kikuo Kurauchi.

1945-1946

Berganti nama menjadi “Gedung Cacar dan Lembaga Pasteur.” Perusahaan ini dipimpin oleh R.M. Sardjito yang merupakan Pemimpin Indonesia pertama. Pada saat kepemimpinan R.M. Sardjito, lokasi sempat dipindahkan ke daerah Klaten.

The Indonesian name of “Gedung Cacar and Lembaga Pasteur” was attributed to the Company, which was then led by R.M. Sardjito, the first Indonesian officer who led the Company. Under his leadership, the head office was moved to Klaten.

1950-1954

Berganti nama menjadi “Gedung Cacar dan Lembaga Pasteur”.

The Company changed its name again to “Gedung Cacar and Lembaga Pasteur”.

1946-1949

Berganti nama menjadi “Landskoepok Inrichting en Instituut Pasteur”.

The company once again was renamed “Landskoepok Inrichting en Instituut Pasteur”.

1955-1960

Pada masa nasionalisasi kepemilikan perusahaan Belanda di Indonesia, berganti nama kembali menjadi “Perusahaan Negara Pasteur”.

During the nationalization of Dutch companies in Indonesia, the Company later changed its name to “Perusahaan Negara Pasteur”.

1961-1978-1996

Perusahaan berubah nama menjadi “Perusahaan Negara Bio Farma”, atau lebih dikenal dengan nama PN Bio Farma. Berdasarkan Peraturan Pemerintah No. 26 tahun 1978, Perusahaan berubah nama menjadi Perusahaan Umum Bio Farma, yang lebih dikenal dengan nama Perum Bio Farma.

The Company changed its name again to “Perusahaan Negara Bio Farma”. Based on Government Regulation No. 26/1978, the Company changed its name to Bio Farma public company.

1997-2011

Bio Farma berhasil mendapatkan Pra-Kualifikasi WHO untuk 12 jenis vaksin sehingga bisa memasuki pasar ekspor.

Bio Farma succeeded in obtaining WHO Prequalification for 12 types of vaccines, marking WHO’s approval for entering the global market.

1997

Berdasarkan Peraturan Pemerintah No. 1 tahun 1997, nama Perusahaan kembali berubah menjadi Perusahaan Perseroan (Persero) atau lebih dikenal dengan nama PT Bio Farma (Persero) sampai dengan saat ini, dengan kepemilikan saham 100% milik pemerintah.

Based on Government Regulation No. 1/1997, the Company changed its name to Perusahaan Perseroan or known as PT Bio Farma (Persero) which 100% shareholding owned by the government.

2008

Peluncuran logo baru mencerminkan semangat dan optimisme untuk menuju industri vaksin kelas dunia.

The launch of a new logo reflected the spirit and optimism towards entry into the world class vaccine industry.

2009

Bio Farma melangkah menuju perusahaan *Life Science* kelas dunia yang berdaya saing global.

Bio Farma is moving forward to become a world class life science company with global competitiveness.

2015

Vaksin Pentabio berhasil memasuki pasar ekspor internasional perdana ke Arab Saudi.

Pentabio vaccine succeeded for firstly penetrating in international market to Saudi Arabia.

2020

Pembentukan Holding BUMN Farmasi, dimana Bio Farma dipercaya untuk bertindak sebagai Induk Holding Bio Farma.

Dipercaya menjadi produsen vaksin Covid-19 yang akan diproduksi massal di tahun 2021.

Establishment of SOE's Pharmaceutical Holding, in which Bio Farma is trusted to act as Holding.

Trusted to be a producer of the Covid-19 vaccine which will be mass produced in 2021.

2014

Peningkatan Visi baru "Menjadi Perusahaan *Life Science* Kelas Dunia yang Berdaya Saing Global". Vaksin Pentabio (DTP-HB-Hib) mendapatkan pengakuan Pra-Kualifikasi dari WHO.

Enhancement of the new Vision, "To be a World Class Life Science Company with Global Competitiveness". Pentabio vaccine (DTP-HB-Hib) attained recognition in Pre-Qualification from WHO.

2018

Indonesia resmi sebagai Centre of Excellence(CoE) The Organization of Islamic Cooperation (OIC). Bio Farma sudah mempersiapkan beberapa langkah konkret sebagai mekanisme kerja sama antarsesama anggota OKI.

Indonesia has officially become the Center of Excellence (CoE) The Organization of Islamic Cooperation (OIC). Bio Farma has prepared several concrete steps as a cooperation mechanism between OIC members.

● Peran Bio Farma

Role of Bio Farma

Kami berperan aktif dalam mengembangkan riset vaksin dan produk *Life Science*, melakukan penelitian vaksin baru dalam menjamin kemandirian kebutuhan vaksin dalam negeri serta ketersediaan vaksin untuk memenuhi kebutuhan vaksin dunia.

Penelitian & Pengembangan Vaksin untuk Kebutuhan Nasional dan Global

Research & Development for Self-Reliance of National Research

Kesehatan menjadi hal yang fundamental bagi kehidupan suatu negara dan dalam berhubungan dengan negara lain. Bahkan saat ini, kesehatan menjadi salah satu primadona baru dalam berdiplomasi antar negara, terlebih lagi di saat pandemi COVID-19 seperti sekarang.

Bio Farma memiliki peran strategis baik di dalam maupun di luar negeri. Peran di dalam negeri yang utama adalah untuk peningkatan daya saing farmasi nasional. Sedangkan peran strategis luar negeri, Bio Farma memiliki peran untuk ikut serta dalam *global health security* dengan menyediakan vaksin yang berkualitas sesuai dengan standar WHO, dan meningkatkan peran Indonesia di negara berkembang yang tergabung dalam Developing Countries Vaccine Management Network (DCVMN) dan Organisation of Islamic Cooperation (OIC), untuk menghasilkan vaksin yang berkualitas dan harga terjangkau.

We play an active role in developing vaccine research and Life Science product, conduct new vaccine research in ensuring self-reliance of domestic vaccine needs and the availability of vaccine to meet the needs of the world's vaccines.

Health becomes fundamental to the life of a country and in dealing with other countries. Even today, health is one of the new prima donnas in diplomacy between countries, especially during the COVID-19 pandemic at nowadays.

Bio Farma has a strategic role both domestically and abroad. The main role in the country is to increase the competitiveness of national pharmaceuticals. While the strategic role abroad, Bio Farma has a role to participate in global health security by providing quality vaccines in accordance with WHO standards, and increasing Indonesia's role in developing countries incorporated in the Developing Countries Vaccine Management Network (DCVMN) and the Organization of Islamic Cooperation (OIC), to produce quality and affordable vaccines.

Di tengah kondisi pandemi COVID-19, Bio Farma pun memiliki peran yang besar yaitu dengan menyiapkan 5 skenario penanganan COVID-19, diantaranya yaitu:

In the midst of the COVID-19 pandemic, Bio Farma has a big role by preparing 5 scenarios for handling COVID-19, such as:

01



Memproduksi Kit Diagnostik Real Time Polymerase Chain Reaction (RT-PCR).

Producing Diagnostic Kit in the form of Real Time Polymerase Chain Reaction (RT-PCR).

02



Membantu penelitian plasma konvalesen, hasil kerjasama dengan Rumah Sakit Pusat Angkatan Darat (RSPAD) Gatot Subroto.

Assisting convalescent plasma research, in collaboration with the Army Central Hospital (RSPAD) Gatot Subroto.

03



Pembuatan mobile lab dengan standar Bio Safety Level 3 (BSL 3).

Manufacture of mobile lab with Bio Safety Level 3 standard (BSL 3).

04



Pembuatan Bio Viral Transfer Medium (VTM).

Making Bio Viral Transfer Medium (VTM).

05



Pengembangan vaksin COVID-19.

Development of COVID-19 vaccine.

● **Kemitraan Strategis Global** *Strategic Global Partnership*

Bio Farma menjalin kemitraan dengan berbagai pihak dalam sektor riset dan integrasi teknologi, pemasaran, rantai pasokan, keuangan, agar tetap eksis, relevan dan berkontribusi di industri vaksin global.

Bio Farma establishes partnerships with various parties in the sectors of research and technology integration, marketing, supply chain, finance, in order to remain present, relevant and contribute to the global vaccine industry.



● Proses Bisnis Kami *Our Business Process*

Bio Farma memiliki komitmen untuk menghasilkan produk yang halal sesuai dengan syariat Islam sejak dari proses penelitian, dengan tetap mengedepankan unsur *safety, efficacy* dan *quality* yang sesuai dengan Cara Pembuatan Obat yang Baik (CPOB) maupun dari Current Good Manufacturing Process (CGMP) dari WHO.


Bio Farma has a commitment to produce Halal products in accordance with Islamic law since the research process, by putting forward elements of Safety, Efficacy and Quality in accordance with the Indonesian Good Manufacturing Practice (GMP) and/or the Current Good Manufacturing Process (CGMP) from WHO.

Proses Pengembangan Vaksin

Vaccine Development Process

Hanya perubahan paradigma yang dapat memberikan potensi pengembangan vaksin secara cepat dengan standar keamanan yang sesuai.

Only a fundamental paradigm shift provides potential of rapid vaccine development with appropriate safety standards.



Proses Produksi Vaksin

Vaccine Production Process

Proses produksi vaksin memiliki regulasi yang sangat ketat dan kompleks. Proses produksi vaksin ini merupakan ilustrasi dan gambaran secara umum. Proses tersebut tidak menggambarkan produksi semua vaksin atau vaksin tertentu yang dilakukan oleh Bio Farma.

The process of vaccine production has been very strictly regulated and complicated. This production process of vaccine as an illustration and description in general. This process does not describe the production of all or certain vaccines carried out by Bio Farma.

1



Penyiapan Media

Pengambilan bibit virus/bakteri terbaik agar jumlahnya memenuhi kebutuhan pembuatan vaksin.

Media Preparation

Selecting the best virus/bacteria seeds in specified amount.

2



Inokulasi & Kultivasi
Penanaman virus/bakteri pada suatu media yang sudah dimurnikan.
Inoculation & Cultivation
Cultivating virus/bacteria in a purified media.

3



Panen

Proses memanen virus dan bakteri yang ditanam pada media dalam jumlah tertentu.

Harvesting

Harvesting virus and bacteria planted in the media into a specified amount.

4



Inaktivasi

Melakukan pelemahan/inaktivasi virus atau bakteri.

Inactivation

Conducting Attenuation/inactivation of the virus/bacteria.

5



Pemurnian

Melakukan pemurnian virus/bakteri yang sudah tumbuh tersebut dalam proses purifikasi, yaitu suatu proses untuk menghilangkan zat-zat yang tidak relevan dengan produk vaksin.

Purification

Purifying the virus/bacteria that have grown in the purification process, i.e. a process to eliminate the irrelevant substances to vaccine products.

6



Formulasi

Memformulasikan bulk vaksin yang telah dimurnikan dengan zat-zat tambahan.

Formulation

Formulate vaccine in bulk that have been purified by adjuvant.

7



Pengisian dan Pengemasan

Melakukan pengisian vaksin ke dalam kemasan. Pemasangan label pada kemasan vaksin.

Filling and Packaging

Packaging and labelling that vaccine.



● Produk Kami

Our Products

Produk kami telah memenuhi standar kualifikasi dari Badan Pengawas Obat dan Makanan RI (Badan POM) dan Badan Kesehatan Dunia (WHO) sehingga terjamin keamanan, kualitas dan keampuhannya.

Our products have met the qualification standards of the National Agency of Drug & Food Control (NADFC) and the World Health Organization (WHO) so that it is guaranteed safety, quality and efficacy.



Vaksin Virus
Viral Vaccines



Flubio Vaksin Influenza HA
Pencegahan terhadap penyakit flu akibat infeksi virus *influenza* untuk daerah Northern Hemisphere (NH).

Flubio Influenza HA Vaccine
Prevention of flu disease due to influenza virus infection for the Northern Hemisphere (NH) region.



Indovac (Vaksin COVID-19 Rekombinan)
Pencegahan terhadap infeksi COVID-19 akibat virus SARS CoV-2.

Indovac (Recombinant COVID-19 Vaccine)
Prevention against COVID-19 infection caused by the SARS-CoV-2 virus.



nOPV2 (Novel Oral Poliomyelitis Vaccine)
Pencegahan penyakit polio akibat infeksi virus polio tipe 2.

nOPV2 (Novel Oral Poliomyelitis Vaccine)
Prevention of polio disease due to infection with polio virus types 2.



NusaGard
Pencegahan Penyakit oleh Human Papillomavirus (HPV) Onkogenik tipe 16 dan 18 seperti kanker serviks, pre kanker vulva, pre kanker vagina; serta HPV non Onkogenik tipe 6 dan 11 seperti kutil kelamin.

NusaGard
Prevention of Disease by Oncogenic Human Papillomavirus (HPV) type 16 and 18 such as cervical cancer, pre-vulvar cancer, pre-vaginal cancer, as well as non-Oncogenic HPV types 6 and 11 such as genital warts.



Vaksin Campak (Beku Kering)
Pencegahan terhadap penyakit campak akibat infeksi virus campak.

Measles Vaccine (Freeze Dried)
Prevention of measles due to measles virus infection.



Vaksin Covid-19 Bio Farma
Pencegahan terhadap infeksi COVID-19 akibat virus SARS CoV-2.

Bio Farma Covid-19 Vaccine
Prevention against COVID-19 infection caused by the SARS-CoV-2 virus.



Vaksin Hepatitis B Rekombinan
Pencegahan terhadap penyakit peradangan pada organ hati akibat infeksi virus hepatitis B.

Hepatitis B Recombinant Vaccine
Prevention of inflammatory liver disease due to hepatitis B virus infection.



Vaksin Poliomyelitis Inaktif
Pencegahan penyakit polio akibat infeksi virus polio tipe 1 dan 3.

Inactivated Poliomyelitis Vaccine
Prevention of polio disease due to infection with polio virus types 1 and 3.



Vaksin Poliomyelitis Oral Bivalen Tipe 1 & 3 (bOPV)
Pencegahan terhadap penyakit poliomyelitis tipe 1 & 3.

Bivalent Type 1 & 3 Oral Poliomyelitis Vaccines (bOPV)
Vaccines for the prevention of poliomyelitis type 1 & 3 diseases.

Vaksin Bakteri
Bacterial Vaccines



Vaksin Poliomyelitis Oral Monovalen Tipe 1 (mOPV1)
Pencegahan terhadap penyakit poliomyelitis tipe 1 dan 3.

Monovalen Oral Poliomyelitis Vaccines Type 1 (mOPV1)
Vaccines for the prevention of poliomyelitis type 1 & 3 diseases.



Vaksin Poliomyelitis Oral Monovalen Tipe 2 (mOPV2)
Untuk pencegahan terhadap penyakit poliomyelitis tipe 2.

Monovalen Oral Poliomyelitis Vaccines Type 2 (mOPV2)
For prevention against poliomyelitis type 2.



BIO TCV
Pencegahan penyakit demam tifoid akibat infeksi bakteri *salmonella typhi*.

BIO TCV
Prevention of typhoid fever caused by *salmonella typhi* bacterial infection.



Vaksin BCG (Beku Kering)
Pencegahan terhadap penyakit yang disebabkan oleh infeksi *mycobacterium tuberculosis*.

BCG Vaccine (Freeze-Dried)
Prevention of diseases caused by *mycobacterium tuberculosis* infection.



Vaksin BIO-Td (Vaksin Jerap Td)
Pencegahan terhadap penyakit difteri dan tetanus pada individu mulai usia 7 tahun.

BIO-Td Vaccine
Prevention against tetanus and diphtheria disease for children aged 7 years and over.



Vaksin BIO-TT
Pencegahan terhadap penyakit tetanus dan perlindungan terhadap tetanus neonatorum pada wanita usia subur.

BIO-TT Vaccines
Prevention against tetanus disease and protection against tetanus neonatorum in women of childbearing age.



Vaksin DTP
Vaksin DTP merupakan suspensi koloidal homogen berwarna putih susu dalam vial gelas, mengandung toksoid tetanus murni, toksoid difteri murni, dan bakteri pertusis yang diinaktivasi, yang teradsorbsi kedalam aluminium fosfat.

DTP Vaccine
DTP vaccine is a white homogeneous colloidal suspension, in glass vial, containing purified diphtheria toxoid, purified tetanus toxoid, and inactivated *B. pertussis* organisms. The toxoids are adsorbed onto aluminum phosphate.



Vaksin Jerap DT
Pencegahan terhadap penyakit difteri dan tetanus.

Adsorbed DT Vaccine
Prevention against diphtheria and tetanus diseases.



Vaksin Jerap Td 10 Dosis
Pencegahan terhadap penyakit difteri dan tetanus pada individu mulai usia 7 tahun.

Adsorbed Td Vaccine 10 doses
Prevention against tetanus and diphtheria disease for children aged 7 years and over.



Vaksin TT
Pencegahan terhadap penyakit tetanus dan perlindungan terhadap tetanus neonatal pada bayi baru lahir.

TT Vaccine
Prevention of tetanus and tetanus neonatal disease (Tetanus in newborns).



Vaksin DTP
Pencegahan terhadap penyakit difteri, tetanus, dan pertusis.

DTP Vaccine
Prevention of diphtheria, tetanus and pertussis diseases.


Vaksin Kombinasi
Combination Vaccine



Vaksin Pentabio (DTP-HB-Hib)
Pencegahan terhadap penyakit difteri, tetanus, pertusis (batuk rejan), hepatitis B, dan infeksi *haemophilus influenzae* tipe b secara simultan.

Pentabio (DTP-HB-Hib Vaccine)
Simultaneous prevention of diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and *haemophilus influenzae* type b infection.

Diagnostik
Diagnostic



BioColoMelt-Dx
BioColoMelt-Dx is a molecular diagnostic kit designed to detect genetic abnormalities primarily occurring in colorectal cancer patients. The results of the BioColoMelt-Dx examination provide information about the cancer mutation profile that can be used by doctors or other medical professionals to determine the type of medication that offers the most optimal therapeutic response for colorectal cancer patients. Additionally, BioColoMelt-Dx can also be used for screening Lynch syndrome, a condition that can increase an individual's risk of developing various types of cancers and is hereditary.

BioColoMelt-Dx
BioColoMelt-Dx adalah kit diagnostik molekuler untuk mendeteksi kelainan genetik yang terutama terjadi pada kanker kolorektal. Hasil pemeriksaan BioColoMelt-Dx berupa informasi profil mutasi kanker yang dapat digunakan oleh dokter atau tenaga medis lainnya untuk menentukan jenis obat yang memberikan respon terapi paling optimal pada pasien kanker kolorektal tersebut. Selain itu, BioColoMelt-Dx juga dapat digunakan untuk penapisan (screening) lynch syndrome, suatu kondisi yang dapat meningkatkan risiko seseorang untuk mengidap berbagai macam kanker dan bersifat keturunan.



Flodeg-18
A fluorodeoxyglucose (FDG-18)-based radiopharmaceutical product used in PET scans to aid in the detection of cancer, neurological disorders, and heart disease.

Flodeg-18
Produk radiofarmaka berbasis Fluorodeoxyglucose (FDG-18) yang digunakan pada pemeriksaan PET scan untuk membantu deteksi kanker, kelainan saraf, dan gangguan jantung.



BioSaliva
Media pembawa virus SARS-CoV-2 dengan metode non-invasif yang memberikan kenyamanan lebih pada pasien dan tingkat keamanan yang lebih baik bagi tenaga kesehatan, yaitu dengan metode gargle saliva.

BioSaliva
The SARS-CoV-2 virus transport medium with non-invasive method that provides more comfort for patients and a better level of safety for health workers, namely the saliva gargle method.



BioVTM
Media pembawa virus yang berupa cairan jernih steril yang digunakan sebagai media perantara dalam pemeriksaan SARS-CoV-2.

BioVTM
The virus carrier medium, a clear sterile liquid used as an intermediary medium in the examination of SARS-CoV-2.



FastBio-RBD

Kit deteksi titer antibodi RBD-SARS-CoV-2 semikuantitatif berbasis fluorescence immunoassay. FastBio-RBD 2019-nCoV Neutralizing antibody Test digunakan bersamaan dengan FastBio-RBD Fia Meter.

FastBio-RBD

A semi-quantitative fluorescence immunoassay-based kit for detecting the antibody titer of RBD-SARS-CoV-2. The FastBio-RBD 2019-nCoV Neutralizing Antibody Test is used in conjunction with the FastBio-RBD Fia Meter.



mBioCoV-19 RxReady

Kit One Step Real Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) multiplex untuk mendeteksi keberadaan virus SARS-CoV-2 dengan penggunaan reagen yang berbentuk ready mix.

mBioCoV-19 RxReady

One-step real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) multiplex kit for detecting the presence of the SARS-CoV-2 virus using ready mix reagents.




CerviScan

CerviScan merupakan kit diagnostik berbasis RT-PCR untuk deteksi 14 tipe virus HPV high risk penyebab kanker serviks. Sampel yang digunakan dapat berupa urin dan apusan lendir serviks.

CerviScan

CerviScan is an RT-PCR-based diagnostic kit for the detection of high risk HPV infection, the leading cause of cervical cancer. The samples used can be urine and cervical mucus smears.



Tuberkulin PPD RT 23

Tuberkulin PPD RT 23 merupakan kit diagnostik yang digunakan pada uji mantoux untuk menentukan apakah seseorang pernah terinfeksi oleh mycobacterium tuberculosis.

Tuberkulin PPD RT 23

Tuberculin PPD RT 23 is a diagnostic tool used for Mantoux tuberculin skin testing to help diagnose if a person has ever been infected with Mycobacterium tuberculosis.



VarScreen RxReady mBioCoV-19+

VarScreen RxReady mBioCoV-19+ adalah kit RT-PCR yang secara simultan dapat digunakan untuk deteksi dan identifikasi varian virus SARS-CoV-2 melalui kombinasi inovatif 4 gen target SGTF (S Gene Target Failure) dan delesi 1 gen ORF1ab.

VarScreen RxReady mBioCoV-19+

VarScreen RxReady mBioCoV-19+ is an RT-PCR kit that can simultaneously be used for the detection and identification of SARS-CoV-2 virus variants through an innovative combination of 4 SGTF target genes (S Gene Target Failure) and deletion of 1 ORF1ab gene.



mBioCoV-19 RT-PCR Kit

Kit One Step Real Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) multiplex untuk mendeteksi keberadaan virus SARS-CoV-2.

mBioCoV-19 RT-PCR Kit

One-step real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) multiplex kit for detecting the presence of the SARS-CoV-2 virus.

Sera
Sera



Serum Anti Difteri (BioADS)

Pengobatan terhadap penyakit difteri dengan cara menetralkan toksin yang dihasilkan oleh bakteri corynebacterium diphtheriae.

Anti-Diphtheria Serum (BioADS)

Treatment for diphtheria by neutralizing toxin produced by corynebacterium diphtheriae bacterial.



Serum Anti Tetanus 1500 UI (BioSAT 1.5)

Pencegahan dan pengobatan terhadap tetanus yang disebabkan oleh infeksi clostridium tetani.

Anti Tetanus Serum 1,500 IU (BioSAT 1.5)

Used for prevention and treatment against tetanus may cause infection due to clostridium tetani.



Serum Anti Bisa Ular (BioSAVE)

Pengobatan terhadap gigitan ular berbisa yang bersifat neurotoksik (seperti ular dari jenis Naja sputatrix - Ular Kobra, Bungarus fasciatus - Ular Belang) dan yang bersifat hemotoksik (ular Agkistrodon rhodostoma - Ular Tanah) yang banyak ditemukan di Indonesia.

Anti-Snake Venom Serum (BioSave)

Treatment for bites from venomous snakes which are neurotoxic (such as Naja sputatrix, Bungarus fasciatus) and which are hemotoxic (Agkistrodon rhodostoma) which are often found in Indonesia.

Lainnya
Others



Enoxaparin Sodium

Enoxaparin Sodium merupakan obat antikoagulan (pengencer darah) yang berperan dalam mencegah pembekuan darah dan mengobati penyakit akibat bekuan darah (*thrombus*).

Enoxaparin Sodium

Enoxaparin sodium is an anticoagulant drug (blood thinner) which plays a role in preventing blood clots and treating diseases caused by blood clots (thrombus).



Vaccarbio

Electronic Portable Cooler produksi dalam negeri untuk menjaga suhu vaksin tetap stabil di suhu 2 - 8° C dengan ketahanan casing body di suhu ambient -5 s.d 45° C. VaccarBio dilengkapi dengan Battery Back-up yang dapat tahan hingga 7 jam.

Vaccarbio

Domestic-produced Electronic Portable Cooler is designed to maintain the temperature of vaccines stable at 2 - 8°C, with the casing body's endurance ranging from an ambient temperature of -5 to 45°C. VaccarBio is equipped with a Battery Back-up that can last for up to 7 hours.

Product Partnership
Partnership Product



Bio-PCV

Pencegahan penyakit akibat infeksi bakteri *streptococcus pneumoniae* seperti pneumonia, meningitis, dan sinusitis.

Bio-PCV

Prevention of diseases caused by Streptococcus pneumoniae bacterial infections such as pneumonia, meningitis and sinusitis.



Vaksin BCG (Beku Kering)

Pencegahan penyakit tuberkulosis (TB) akibat infeksi bakteri *mycobacterium tuberculosis*.

BCG Vaccine (Freeze-dried)

Prevention of tuberculosis (TB) due to infection with the mycobacterium tuberculosis bacteria.



Diphtheria Antitoxin (DAT)

Pengobatan terhadap penyakit difteri dengan cara menetralisasi toksin yang dihasilkan oleh bakteri *corynebacterium diphtheriae*.

Diphtheria Antitoxin (DAT)

Treatment for diphtheria by neutralizing toxin produced by corynebacterium diphtheriae bacterial.



Flubio HL

Pencegahan terhadap penyakit flu akibat infeksi virus influenza untuk daerah Northern Hemisphere (NH).

Flubio HL

Prevention of flu disease due to influenza virus infection for the Northern Hemisphere (NH) region.



Vaksin Menivax ACYW (Meningitis)

Pencegahan penyakit meningitis *meningokokus* akibat infeksi bakteri *neisseria meningitidis*.

Menivax ACYW Vaccine (Meningitis)

Prevention of meningococcal meningitis due to neisseria meningitidis bacterial infection.



Rotavac

Pencegahan terhadap penyakit peradangan saluran pencernaan akibat infeksi rotavirus.


Rotavac

Prevention of inflammatory diseases of the gastrointestinal tract due to rotavirus infection.



Japanese Encephalitis Vaccine, Live
Pencegahan terhadap penyakit
Japanese Encephalitis (radang otak
Jepang).

Japanese Encephalitis Vaccine, Live
Prevention of Japanese Encephalitis
(Japanese brain inflammation)
disease.



**Vaksin Campak dan Rubella, Live,
attenuated (Beku Kering)**
Pencegahan terhadap penyakit
campak dan rubella.

*Vaksin Campak dan Rubella, Live,
attenuated (Freeze-Dried)*
*Prevention against measles and
rubella.*



**Polyvalent Snake Antivenom (Serum
Anti Bisa Ular II)**
Pengobatan dari gigitan ular berbisa
bagian Indonesia Timur.

*Polyvalent Snake Antivenom (Serum
Anti Bisa Ular II)*
*Treatment for venomous snake
bites in East Indonesia.*



Varicella Vaccine, Live
Pencegahan terhadap penyakit
varicella (cacar air).

Varicella Vaccine, Live
Prevention against varicella
(chickenpox) disease.

● Distribusi dan Pemasaran Kami

Our Distribution And Marketing



Bio Farma merupakan produsen vaksin terbesar di Asia Tenggara, dengan kapasitas produksi mencapai 3,5 miliar dosis per tahun untuk memenuhi kebutuhan vaksin nasional dan global, termasuk kebutuhan vaksin untuk Jemaah Haji dan Umrah.

Bio Farma is the largest Vaccine Manufacturer in Southeast Asia, with the production capacity of more than 3,5 billion doses per year to fulfill vaccine needs nationally and globally, including vaccine needs for pilgrims of hajj and umrah.



“

Bio Farma Telah Berkontribusi untuk Meningkatkan Kualitas Hidup Bangsa Indonesia dan Dunia.

Bio Farma has Contributed in Improving the Quality of Life Among the People in Indonesia and the World.

”

Bio Farma berperan aktif dalam meningkatkan ketersediaan dan kemandirian produksi vaksin di negara-negara berkembang dan negara-negara Islam untuk menjaga keamanan kesehatan global.

Bio Farma plays an active role in increasing the availability and sustainability of vaccine in developing countries including Islamic countries to safeguard global health security.


Akses untuk Mendapatkan Vaksin

Access to Vaccines

Bio Farma membantu memberikan akses untuk mendapatkan vaksin untuk negara berkembang dan wilayah yang sulit terjangkau.

Bio Farma enhancing access to vaccines in developing countries and donation of vaccine to remote area both in Indonesia and global.





Vaksin merupakan alat yang paling efektif untuk mencegah dan menghentikan pandemi penyakit menular. Untuk itu diperlukan pemerataan penyebaran vaksin baik di Indonesia maupun diseluruh dunia. Bio Farma membantu memberikan akses untuk mendapatkan vaksin bagi negara berkembang dan wilayah yang sulit terjangkau, sehingga seluruh generasi bangsa menjadi bangsa yang kuat dan terhidar dari penyakit yang dapat menimbulkan kecacatan bahkan kematian.

Vaccines are an effective tool to prevent and stop infectious disease pandemics. Therefore, distribution of vaccines must fairly distributed, both in Indonesia and around the world. Bio Farma helps to provide access of vaccines for developing countries and hard-to-reach regions, so that the entire generation of nation becomes a strong nation and avoid diseases that could cause physical disabilities and even death.

Menjaga Kualitas Vaksin

Maintaining The Quality of Vaccines

Vaksin merupakan produk biologi yang memerlukan penanganan khusus dalam pendistribusiannya. Diperlukan sistem khusus untuk pendistribusian vaksin, yaitu Sistem Rantai Dingin (*Cold Chain System*) dimulai dari pabrik, pendistribusian, penyimpanan di tempat tujuan, penyimpanan selama vaksin belum digunakan hingga diberikan kepada pelanggan.

Suhu dari vaksin harus tetap terjaga pada suhu kisaran 2-8 derajat celcius untuk vaksin BCG, DTP, TT, DT, Td, DTP-HB-Hib, Campak, Hepatitis B, Influenza. Sedangkan untuk vaksin Polio harus disimpan pada suhu -20 (minus 20) derajat celcius.

Vaccine is a biological product that requires special handling in its distribution. It takes a special system to distribute vaccines, which is Cold Chain System, starting from the manufacturer, distribution, storage at the destination, the storage of stocked vaccines until delivered to the customers.

The vaccine temperature must be maintained in the range of 2 to 8 degrees Celsius for BCG vaccine, DTP, TT, DT, Td, DTP - HB - Hib, Measles, Hepatitis B, Influenza. While the Polio vaccine must be stored at -20 (minus 20) degrees Celsius.

Sistem Manajemen Distribusi Vaksin

The Vaccine Distribution Management System

Bio Farma memanfaatkan teknologi digital untuk proses pendistribusian vaksin dengan menggunakan Sistem Manajemen Distribusi Vaksin (SMDV) yang terintegrasi termasuk *Command Center* yang dilengkapi dengan dashboard *Internet of Things* (IoT), untuk memonitor segala kondisi yang terjadi dalam perjalanan, termasuk batasan suhu yang dipantau secara *real time*, lokasi, kecepatan dan kondisi darurat lainnya; dan *dashboard tracking* vaksin untuk memonitor pergerakan vaksin sehingga kedepannya tidak akan ada lagi berita vaksin palsu, atau produk farmasi yang tidak teregister namun berada di pasaran.

Bio Farma utilizes digital technology for vaccine distribution process using integrated Vaccine Distribution Management System (SMDV) including Command Center equipped with Internet of Things (IoT) dashboard, to monitor all vaccine distribution conditions, including temperature restrictions monitored in real time, location, speed and other emergencies; and dashboard tracking vaccines to monitor the movement of vaccines so there is no more counterfeit vaccine news, or pharmaceutical products that are not registered in the market.

VACCINE PRODUCT IDENTIFICATION



(01)07612345678900(17)100503
(10)AC3453G3(21)1234

GS1 Data Matrix

ISO/IEC 16022 Data Matrix

- Item Identifier
- Expiry Date
- Batch Number
- Serial Number



Primary
Packaging



Secondary
Packaging

Bio Farma
Distribution
System



Internet



Tertiary
Packaging



Track & Trace
Product Information
Database

Kontribusi Bio Farma untuk Dunia

*Bio Farma's Contribution
to the world*



Lebih dari

150

Negara

Telah Menggunakan
Vaksin Bio Farma

*More than 150 Countries
Have Used Bio Farma
Vaccine Product*





Kapasitas Produksi
Lebih Dari

3,5 Miliar
Dosis
per Tahun

*The production capacity more
than 3,5 billion doses per year*



Lebih dari

50
Negara

Anggota Organisasi
Kerja Sama Islam

*More than 50 Member
Countries of Organization
Islamic Cooperation*



MARKETING & DISTRIBUTION

Divisi Ekspor dan Pengembangan Bisnis
Jl. Pasteur No.28 Bandung 40161
Indonesia
Tel: (62)22 203 3755
Fax: (62)22 204 1306
E-mail: sales@biofarma.co.id

For International Supply and
Distribution Please Call:

International Marketing Division
Jl. Pasteur No.28 Bandung 40161
Indonesia
Tel: (62)22 203 3755
Fax: (62)22 204 1306
E-mail: sales@biofarma.co.id

● Sumber Daya Manusia *Our People*

Kami didukung oleh SDM yang handal dari berbagai disiplin ilmu. SDM Bio Farma merupakan tenaga profesional yang memiliki kompetensi dan keahlian (*expertise*) dari latar belakang pendidikan dari dalam dan luar negeri, serta memiliki kompetensi yang unik dalam teknologi farmasi terbaru, khususnya *Biotechnology & Life Science*.

We are supported by reliable human resources from various disciplines. Bio Farma's Human Resources are professionals who have the competence and expertise from educational backgrounds in domestic and abroad, and have unique competencies in the latest pharmaceutical technology, especially Biotechnology & Life Science.

● Tanggung Jawab Kami *Our Responsibilities*

Kami berkomitmen penuh untuk dapat tumbuh bersama lingkungan, sosial kemasyarakatan, pelanggan, serta karyawan.

We are fully committed and responsible to grow with the environment, social, products and employees.

Tanggung Jawab Terhadap Karyawan *Responsibility to the Employees*

Meningkatkan Kenyamanan Lingkungan Kerja *Improving the Friendly Working Environment*

Kami bertanggung jawab terhadap karyawan dengan menciptakan Keselamatan dan Kesehatan Kerja (K3). Dengan manajemen K3, kami meraih Zero Accident Award dan OHSAS 18001:2007 sejak tahun 2006 hingga sekarang.

We are responsible to employees by implementing Occupational Health and Safety Assessment Series (OHSAS 18001:2007). With the OHSAS management, we have achieved Zero Accident Awards since 2006 to present day.

● **Tanggung Jawab Produk** *Our Responsibilities to the product*

Keamanan Produk Menjadi Prioritas Kami

Product Safety is Our Priority

Kami memiliki produk aman dan berkualitas dengan menerapkan Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), Good Regulatory Practices (GRP), Good Clinical Practices (GCP), Good Distribution Practices (GDP), ISO 9001, ISO 14001 dan OHSAS 18001.

Prosedur pengawasan dan jaminan mutu dipantau Badan Pengawas Obat dan Makanan (BPOM) yang diakui Badan Kesehatan Dunia (WHO).

We have safe and high quality products by applying Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), Good Regulatory Practices (GRP), Good Clinical Practices (GCP), Good Distribution Practices (GDP), ISO 9001, ISO 14001, and OHSAS 18001.

The procedure of Quality Control and Assurance is closely monitored by the National Agency of Drug & Food Control (NADFC) which is acknowledged by WHO.

Pra-Kualifikasi WHO (PQ WHO) Menjadi Kunci Keamanan Produk Kami

World Health Organization Pre-Qualifications (WHO's PQ) is the Key of Our Products Safety

Badan Kesehatan Dunia (WHO) menghimbau negara anggota menggunakan vaksin imunisasi yang memenuhi persyaratan WHO. Sejak 1997, kami mengikuti prosedur Sistem Manajemen Mutu sehingga mendapatkan pengakuan Pra-kualifikasi WHO.

The World Health Organization (WHO) has recommended all its country members to use only vaccines that have met the WHO's requirements. Since 1997, we have been implementing an integrated system procedure and Quality Management System, and has been recognized for WHO Pre-qualification.

Uji Klinis

Clinical Trial

Kami melakukan clinical trial atau uji klinis untuk menjamin keamanan produk dari efek samping yang dapat ditimbulkan. Untuk mengetahui efektivitas produk, keamanan kualitas dan kemampuan vaksin, tahapan uji klinis terdiri dari tahapan 1, 2 dan 3.

Kami melakukan sinergi dengan berbagai universitas, lembaga riset dan BPOM. Setelah produk vaksin diluncurkan, kami melakukan uji klinis tahap 4.

We perform clinical trial process to ensure product safety from side effects that can be caused. To determine the effectiveness of the product, the safety, quality and efficacy of the vaccine, the clinical trials consist of stage 1, 2 and 3.

We collaborate with various universities, research institutions and NADFC (National Agency of Drugs and Food Control). After the vaccine product is released, we conduct the stage 4 (four) clinical trial (Post Marketing Surveillance).



● Create Share Value



Bagi kami, *“Dedicated to Improving Quality of Life”* bukanlah sekedar filosofi semata. Tanggung jawab atas lingkungan hidup terutama didasarkan pada prinsip *“No One Leave Behind”* dengan mengimplementasikan *Sustainable Development Goals (SGDs)*. Hal ini bermakna bahwa Bio Farma memiliki prinsip untuk maju bersama dengan masyarakat, khususnya yang berada di sekitar kami.

Melalui kompetensi yang dimiliki oleh Bio Farma dalam bidang *Life Science*, kami ingin membagikan pengetahuan, keahlian dan kompetensi dalam bidang *Life Science*, kepada masyarakat melalui program *Create Share Value (CSV)*. Tujuan akhir dari kegiatan ini adalah untuk menciptakan keberlanjutan pada komunitas sosial yang ada di sekitar perusahaan (*Sustainable Local Communities*).

For us, “Dedicated to improving Quality of Life” is not just a philosophy. Responsibility for the environment is primarily based on the principle of “No One Leave Behind” by implementing Sustainable Development Goals (SGDs). This means that Bio Farma has principle to move forward together with the community, especially those around us.

Through the competence owned by Bio Farma in Life Science, we want to share knowledge, expertise and competence in Life Science, to the community through Create Share Value (CSV) program. The ultimate goal of this activity is to create sustainability in the social communities around the company (Sustainable Local Communities).

Kegiatan CSV merupakan salah satu upaya untuk mewujudkan tujuan dari Pembangunan Berkelanjutan (SDGs) 2030, dalam bidang; Tanpa Kemiskinan, Tanpa Kelaparan, Pekerjaan yang Layak dan Pertumbuhan Ekonomi, Berkurangnya Kesenjangan, Konsumsi dan Produksi yang bertanggung jawab dan Penanganan Perubahan Iklim.

CSV activities are one of efforts to realize the objectives of Sustainable Development (SDGs) 2030, in the sector; No Poverty, Zero Hunger, Decent Work and Economic Growth, Reduced Inequalities, Responsible Consumption and Production and Climate Action.



Pemberdayaan masyarakat selalu berkorelasi dengan kemandirian ekonomi masyarakat penerima manfaat. Bio Farma menerapkan prinsip-prinsip pemberdayaan, antara lain; partisipatif, edukatif, inklusif, integratif.

Community empowerment is always correlated with economic independence for beneficiaries. Bio Farma applies the principles of empowerment, among others; Participatory, Educational, Inclusive, Integrative.



Head office: Jl. Pasteur No. 28
Bandung Jawa Barat 40161

Representative office: Pakarti Centre Lantai 7
Jl. Tanah Abang III Jakarta 10160

Phone +62 22 2033755
www.biofarma.co.id

 @biofarmaid







PT Kimia Farma Tbk

● Visi & Misi PT Kimia Farma Tbk

PT Kimia Farma Tbk Vision & Mission

Visi

Menjadi perusahaan *healthcare* pilihan utama yang terintegrasi dan menghasilkan nilai yang berkesinambungan.

Vision

To become the first choice healthcare company that is integrated and produces sustainable value.

Misi

1. Melakukan aktivitas usaha di bidang-bidang industri kimia dan farmasi, perdagangan dan jaringan distribusi, ritel farmasi dan layanan kesehatan serta optimalisasi aset.
2. Mengelola perusahaan secara Good Corporate Governance dan *operational excellence* didukung oleh Sumber Daya Manusia (SDM) profesional.
3. Memberikan nilai tambah dan manfaat bagi seluruh stakeholder.

Mission

1. *Carrying out business activities in the fields of chemical and pharmaceutical industry, trade and distribution networks, pharmaceutical retail and health services as well as asset optimization.*
2. *Manage the company with Good Corporate Governance and operational excellence supported by professional Human Resources (HR).*
3. *Provide added value and benefits for all stakeholders.*





Milestone PT Kimia Farma Tbk

1817

**NV Chemicalien Handle
Rathkamp & Co**

Perseroan pertama kali didirikan oleh Hindia Belanda dengan nama NV Chemicalien Handle Rathkamp & Co sebagai perusahaan farmasi pertama di Indonesia.

**NV Chemicalien Handle
Rathkamp & Co**

The company was first founded by the Dutch East Indies under the name NV Chemicalien Handle Rathkamp & Co as the first pharmaceutical company in Indonesia.

2001

Perusahaan Publik

Pada tahun 2001, PT Kimia Farma melakukan IPO di Bursa Efek Jakarta.

Public Company

In 2001, PT Kimia Farma conducted an IPO on the Jakarta Stock Exchange.

1971

**Perubahan menjadi PT
Kimia Farma**

Mengubah nama usahanya menjadi PT Kimia Farma pada tahun 1971.

**Change to PT Kimia
Farma**

Changed its business name to PT Kimia Farma in 1971.

2017

Transformasi Digital

Pada tahun 2017, Perseroan berkomitmen untuk fokus pada layanan kesehatan digital.

Digital Transformation

In 2017, the Company is committed to focusing on digital health services.

2020

Pembentukan Holding BUMN Healthcare di bawah Kementerian BUMN

Pengalihan 90,025% saham Kimia Farma yang dimiliki oleh pemerintah kepada PT Bio Farma (Persero) melalui Proses Inbreng (Penyertaan modal non tunai).

Establishment of BUMN Healthcare Holding under the Ministry of BUMN

Transfer of 90.025% of Kimia Farma shares owned by the government to PT Bio Farma (Persero) through the Inbreng Process (non-cash capital investment).

2019

Mengakuisisi Perusahaan Farmasi


Pada tahun 2019, Perseroan mengakuisisi PT Phapros Tbk.


Acquiring a Pharmaceutical Company

In 2019, the Company acquired PT Phapros Tbk.

Struktur PT Kimia Farma Tbk Group

PT Kimia Farma Tbk Group Structure






Kimia Farma Merupakan Perusahaan *Healthcare* Terintegrasi yang Terbesar di Indonesia

Kimia Farma is the Largest Integrated Healthcare Company in Indonesia.

Melalui rantai bisnis hulu hingga hilir yang dimiliki Kimia Farma, memberikan peluang bagi Kimia Farma dan menyediakan pengalaman *best in class* bagi konsumen.

Through its upstream to downstream business chain, Kimia Farma provides opportunities and delivers a best-in-class experience for consumers.



Manufacture of Active Pharmaceutical Ingredients (API)

National Distribution Center (NDC)

Retail Pharmacy


Customer



Production Facility

Trading & Distribution

Clinic & Medical Laboratory



10 Pabrik Manufaktur

Manufacturing Plants

48 Titik Distribusi

Distribution Points

+1247 Apotik

Pharmacies

+400 Klinik

Clinics

+300 Laboratorium Hub and Spoke

Hub and Spoke Laboratories

● Fasilitas Produksi Kimia Farma

Kimia Farma Production Facilities

Kimia Farma memiliki 10 fasilitas produksi yang tersebar di seluruh Indonesia.

Kimia Farma has 10 production facilities spread throughout Indonesia.

Jakarta

Non betalactam, Injection (SVP), Antiretroviral (ARV), Narcotics, Radiopharmaceuticals.

Kimia Farma Sungwun Pharmacopia (Cikarang)

Active pharmaceutical ingredients and high functional chemical.

West Java

Sinkona Indonesia Lestari (Subang)

Quinine & derivatives, Essential oil Non betalactam (tablet, capsule powder, syrup, suspension) and Herbal (tablet, capsule, liquid, powder).

Banjaran

Marin Liza (Bandung)

Tablet, cream, and Effervescent.

Lucas Djaja (Bandung)

Soft gel, ORS and generic

Central Java

Semarang

Castor oil & edible oils, Cosmetics.

Phapros

Non-betalactam, Betalactam, Cephalosporin, Herbal.

Seluruh fasilitas produksi terhubung dengan 48 cabang distribusi di seluruh Indonesia.

All production facilities are connected to 48 distribution branches throughout Indonesia.

Seluruh fasilitas produksi telah memiliki sertifikat CPOB dan sertifikat terkait lain yang dibutuhkan sesuai regulasi.

All production facilities have CPOB certificates and other related certificates required according to regulations.

Plant Banjaran merupakan fasilitas produksi dengan kapasitas terbesar di Asia Tenggara yang dilengkapi dengan IoT.

The Banjaran Plant is a production facility with the largest equipped capacity in Southeast Asia with IoT.

Rapid Test Bali

Tests: pregnancy, Syphilis, Hepatitis C, Covid-19.

Watudakon

Non-betalactam (Semisolid & Semisolid steril, Soft capsule), Antiseptic, Iodine and Iodone salt.



Pengembangan Bahan Baku Obat (BBO) dalam Rangka Ketahanan Farmasi Nasional

Development of Active Pharmaceutical Ingredients (API) for National Pharmaceutical Resilience

KFSP akan memproduksi 28 BBO sampai 2024


(6 diantaranya 10 prioritas teratas kemenkes)

KFSP will produce 28 API till 2024

(6 of them are part of Top 10 Kemenkes Priority)

10 BBO Prioritas Kemenkes

10 Kemenkes Priority API



KFSP = 10 BBO Prioritas Kemenkes
10 Kemenkes Priority API



Eksternal KFSP - 10 BBO Prioritas Kemenkes
10 Kemenkes Priority API



KFSP - Proyeksi BBO diluar Prioritas Kemenkes
API outside Kemenkes Priority Projection





KFSP - BBO yang telah selesai pengembangannya
API which has Completed Development

KFSP target: Menurunkan Impor BBO 17-20%
KFSP target: Decreasing API Import by 17-20%

Road Map BBO KFSP

Legend ▼ Target cumulative decline of Indonesia API import (%)



● Produk Kimia Farma yang Sudah Mendapatkan Sertifikat TKDN Sebanyak 187 Produk

Kimia Farma Products That Have Received TKDN Certificates are 187 Products

Top 10 Produk dengan Persentase Nilai TKDN Tertinggi

Top 10 Products with the Highest TKDN Value Percentage

No	Product	TKDN%
1	ANTIFECT HAND SANITIZER, KEMASAN 5 L	79,80%
2	PARACETAMOL SIRUP	70,00%
3	QUININE DIHYDROCHLORIDE INJEKSI	68,38%
4	ENTECAVIR MONOHYDRATE TSS 1 mg	68,19%
5	ENTECAVIR MONOHYDRATE TSS 0,5 mg CLOPIDOGREL	68,19%
6	BISULFATE TSS 75 mg ATORVASTATIN CALCIUM TRIHYDRATE	68,19%
7	TSS 40 mg ATORVASTATIN CALCIUM TRIHYDRATE TSS 10 mg	67,94%
8	ATORVASTATIN CALCIUM TRIHYDRATE TSS 20 mg QUININE	67,94%
9	SULFATE TSS 200 mg	67,94%
10	QUININE SULFATE TSS 200 mg	66,75%

Sudah menggunakan BBO ex KFSP
Already using API ex KFSP



Pengembangan Produk Inovatif untuk Mendukung Kinerja Perseroan ke Depan

Innovative Product Development to Support the Company's Future Performance

Top of Mind & Customer First Choice

Innovation Strategy

VMS AS A NEW BLOCKBUSTER CATEGORY

FOCUS ON 5 TOP THE ANATOMICAL THERAPEUTIC CHEMICAL (ATC 2)

STRATEGIC PARTNERSHIP WITH LOCAL & GLOBAL INSTITUTIONS

Innovation Focus

NEW CHEMICAL ENTITIES (NCE) & STEM CELL

Jenis Molekul obat baru yang belum pernah ada sebelumnya (contoh: NCE UNAIR, ALGETIKA) Stemcell-RSCM & RS Soetomo.

Types of new drug molecules that have never existed before (example: NCE UNAIR, ALGETIKA) Stemcell-RSCM & Soetomo Hospital.

NEW PRODUCT PORTFOLIO

1ST LICENSE: Produk on patent yang mendapatkan lisensi innovator untuk di produksi lokal (contoh: Molnupiravir).

1ST LICENSE: *On patent product that has received an innovator license for local production (example: Molnupiravir).*

1ST ME TOO (INNOVATOR PRODUCT MANUFACTURED LOCAL IN INDONESIA)

1st Me Too produk copy pertama di Indonesia setelah produk Innovator atau setelah produk baru diproduksi di Indonesia (contoh: Morfin Lepas Lambat, TLE, Fentanyl Injeksi).

1st Me Too first copy product in Indonesia after Innovator product or after new product produced in Indonesia (example: Slow Release Morphine, TLE, Fentanyl Injection).

NEW PRODUCT PORTFOLIO

Produk sebagai portfolio baru bagi Kimia Farma dan menjadi backbone baru di antaranya Vitamin Mineral Supplement/VMS).

Products as a new portfolio for Kimia Farma and a new backbone including Vitamin Mineral Supplement/VMS).

1ST LOCAL:

- Produk innovator blm diproduksi di Indonesia (contoh: Morphine Syrup).
- Produk off patent yg pertama diproduksi di Indonesia (contoh: Sitagliptin).
- Produk baru di Indonesia (contoh: TB Scan).

1ST LOCAL:

- *Innovator products have not yet been produced in Indonesia (example: Morphine Syrup).*
- *The first off patent product produced in Indonesia (example: Sitagliptin).*
- *New products in Indonesia (example: TB Scan).*

ENHANCEMENT

Reformulasi atau penambahan/perubahan bentuk sediaan untuk optimasi *performance* dan memperpanjang *Product Life Cycle*.

Reformulation or addition/change in dosage forms to optimize performance and extend the Product Life Cycle.

BUSINESS & DEVELOPMENT STRATEGY

ACCELERATING PRODUCT AND SERVICE INNOVATION THROUGH STRATEGIC PARTNERSHIP (Pentahelix Scheme)

STRENGTHENING END-TO-END BUSINESS PORTFOLIO

Innovation Focus

WHITE SPACE EXPANSION SERVICES

Pengembangan Layanan bisnis di Untapped Market: Stem Cell, Lab Uji BABE

Business Services Development in Untapped Market: Stem Cell, BABE Test Lab

ACCELERATING PERFORMANCE OF EXISTING BUSINESS

Akselerasi performance terhadap bisnis eksisting dengan ekspansi yang agresif: MARVEE

Accelerate performance of existing businesses with aggressive expansion: MARVEE

DEVELOPING BUSINESS THROUGH ORGANIC & INORGANIC SCHEMES

Penguatan portofolio bisnis melalui organik dan anorganik: LPH Halal Equitrust, Lab Uji Halal

Strengthening business portfolio through organic and inorganic: LPH Halal Equitrust, Halal Test Lab

Pengembangan Segmen Distribusi sebagai Bagian Penting dari Rantai Bisnis

Distribution Segment Development as an Important Part of the Business Chain




Pengembangan Ritel Farmasi sebagai Bagian dari Integrasi Bisnis

Pharmaceutical Retail Development as Part of Business Integration

KFA sebagai ritel farmasi modern mempunyai 5 tipe store sesuai dengan layanan dan segmentasi.

KFA as a modern pharmaceutical retail has 5 types of stores according to service and segmentation.

KF PREMIER



53 OUTLET

Store berukuran besar yang menawarkan produk & layanan terlengkap, termasuk apotek 24 jam, klinik, dokter spesialis, lab, optic corner, dan beauty corner.

Large store offering the most complete products & services, including 24 hour pharmacy, clinic, specialist doctor, lab, optic corner and beauty corner.

KF APOTEK+



458 OUTLET

Store tematik yang berfokus pada perawatan medis tertentu yang dilengkapi dengan fasilitas pendukung seperti in house doctor, klinik, lab, dll.

Thematic stores that focus on certain medical treatments are equipped with supporting facilities such as in-house doctors, clinics, labs, etc.

KF APOTEK



718 OUTLET

Store berukuran kecil hingga sedang, menawarkan obat bebas dan obat resep. Format store standar tanpa pendapatan fasilitas pendukung.

Stores are small to medium sized, offering over-the-counter and prescription medications. Standard store format without supporting facility income.

KF HEALTH AND BEAUTY



8 OUTLET

Store khusus yang berfokus pada penawaran kesehatan dan kecantikan / kosmetik pribadi.

Specialty store focused on health and beauty / personal cosmetics offerings.

KF EKSPRES



10 OUTLET

Outlet sederhana dan minimalis yang terletak di area lalu lintas tinggi menawarkan SKU yang Fast Moving.

Simple and minimalist outlets located in high traffic areas offer Fast Moving SKUs.

● **Pengembangan Klinik dan Laboratorium Medis untuk Memberikan Layanan Kesehatan Berkualitas**
Development of Clinics and Medical Laboratories to Provide Quality Health Services



JAKARTA



BANDUNG



MEDAN



SEMARANG



YOGYAKARTA



AMBON




JAKARTA



SOLO



KARAWANG



BATAM



BALI



BANDUNG

● Pengembangan Digitalisasi Layanan untuk Mempermudah Akses Layanan Kesehatan

Development of Service Digitalization to Facilitate Access to Health Services



#8 app medis
241.748 downloader



#10 app medis
1.095.220 downloader

11247 APOTEK

- 7.547 SKU* OTC terlengkap terdekat
- Upload Resep
- Apotek Langganan
- Chat Apoteker
- Obat Keras-Konsultasi Dokter

400 KLINIK

- Reservasi covid test
- Reservasi dokter di klinik
- Hasil via aplikasi
- Layanan Homecare
- Chat-KonsultasiDokter

LABORATORIUM KLINIK

- Reservasi 198 layanan
- Medical check up
- Hasil via aplikasi
- Layanan Homecare

MARKETING

- Push Notification
- Ads Banner
- Email & WA Blast

PROMOSI & LOYALTY

- Voucher Redeem
- Voucher Corporate
- Point
- Point Redeem

WEB VERSION

- Livin Sukha by Mandiri
- Website




TD PSE (Kominfo)

SIUPMSE (Kemendag)

HAKI (Kemenkumham)

PSEF (Kemenkes)

kimiafarma
mobile





Kantor Pusat: Jl. Veteran No. 9
Jakarta Pusat 10110

Phone : +62 21 3847709
Fax : +62 21 3814441
Call Center : 1500-255
www.kimiafarma.co.id

 @kimiafarma.ind





PT Indofarma Tbk

Visi, Misi dan Budaya Perusahaan

Vision, Mission, and Corporate Culture



Visi

Vision

Menjadi perusahaan *healthcare* Indonesia pilihan utama yang berskala global.

To be the top choice Indonesia healthcare company on global scale.

Misi

Mission

1. Kami adalah perusahaan yang bergerak di bidang kesehatan.
2. Kami memiliki nilai tambah melalui proses bisnis yang terintegrasi dan pengembangan produk yang berbasis teknologi modern.
3. Kami menjamin ketersediaan produk yang berkualitas, lengkap dan terjangkau secara konsisten.
4. Kami berjuang dalam meningkatkan derajat kesehatan dan kualitas hidup yang lebih baik.

1. *We are a healthcare company.*
2. *We have added value through integrated business processes and modern technology-based product development.*
3. *We consistently guarantee the complete availability of quality and affordable products.*
4. *We strive to promote health and better quality of life.*



Jejak Langkah

Milestones

1918

Berawal dari unit produksi kecil di Rumah Sakit Pusat Pemerintah Hindia Belanda yang memproduksi salep dan kasa pembalut.

The story began in a production unit in the Central Hospital of Dutch East Indies Government producing only ointments and gauze pads.

1942

Diambil alih oleh Pemerintah Jepang dibawah Manajemen Takeda Pharmaceuticals.

Taken over by the Japanese Government under Management Takeda Pharmaceuticals.

1981

Penetapan bentuk usaha Perusahaan Umum Indonesia Farma (Perum Indofarma).

Determination of business form of Perusahaan Umum Indofarma (Perum Indofarma).

1931

Unit produksi dipindah ke Manggarai, kemudian dikenal sebagai "Pabrik Obat Manggarai", dan mulai memproduksi tablet dan injeksi.

The production unit was moved to Manggarai, later known as "Pabrik Obat Manggarai", and started to produce tablets and injections.

1950

Diambil alih oleh Pemerintah Republik Indonesia di bawah pengelolaan Departemen Kesehatan.

Taken over by the Government of Republic of Indonesia under the management of the Health Ministry.

1991

Pemindahan aktivitas produksi ke Pabrik Cibitung.

Production activity was moved to Cibitung Factory.

1991

Pemindahan aktivitas produksi ke Pabrik Cibitung.

Production activity was moved to Cibitung Factory.

1988

Pembangunan Pabrik di Cibitung, Bekasi, Jawa Barat di areal seluas 20 Hektar.

Construction of a factory in Cibitung, Bekasi, West Java, on a 20-hectare area.

1996

Pendirian Perseroan Terbatas Indofarma (Persero).

Establishment of Perseroan Terbatas Indofarma (Persero).

2000

Pendirian anak perusahaan PT Indofarma Global Medika.

Establishment of the Company's subsidiary, PT Indofarma Global Medika.

2001

Penawaran Umum Perdana Saham PT Indofarma (Persero) Tbk.

Initial Public Offering of PT Indofarma (Persero) Tbk.

2012

Komersialisasi Indomach, unit usaha Engineering Pharmaceutical.

Commercialization of Indomach, Pharmaceutical Engineering business unit.

2015

Resertifikasi ISO 9001: 2008 Issue 8 No.IDO3/00102 Produksi dan Pemasaran dari SGS Resertifikasi CPOB dari BPOM RI untuk sediaan Tablet Biasa dan Tablet Salut Non Betalaktam, Serbuk Oral Non Betalaktam dan kapsul keras non Betalaktam.

Recertification of ISO 9001:2008, Issue 8 No. IDO3/00102 on Production and Marketing from SGS, GMP recertification from BPOM RI for Regular Tablet and Non-Betalactam Salted Tablets, NonBetalactam Oral Powder and NonBetalactam Hard Capsules.

2011

Kuasi Reorganisasi sebagai awal era percepatan pertumbuhan.

Quasi-Reorganization as the beginning of an era of acceleration to grow.

2013

Diambil alih oleh Pemerintah Republik Indonesia di bawah pengelolaan Departemen Kesehatan.

Taken over by the Government of Republic of Indonesia under the management of the Health Ministry.

2017

Memperoleh sertifikat CPOTB dari BPOM untuk sediaan Ekstrak, Tablet, Kapsul, Serbuk Efervesen, Cairan obat dalam dan serbuk oral. Resertifikasi halal dari LPPOM MUI untuk produk Taburia kategori suplemen dan makanan. Resertifikasi dari LPPOM MUI untuk Sistem Jaminan Halal dengan Kategori Cukup.

Achieved CPOTB certificate from BPOM for dosage forms of Extract, Tablet, Capsule, and Effervescent Powder, Internal medicine liquid and oral powder.

Halal recertification from LPPOM MUI for Taburia products category of supplements and food. Recertification from LPPOM MUI for Halal Assurance System with "Fair" Category.

2019

Memperkuat fondasi dengan menerapkan kebijakan Turnaround Strategy melalui 5 (4+1) strategi dalam rangka meningkatkan kinerja Perseroan.

Strengthening the foundation by implementing Turnaround Strategy policy through 5 (4 + 1) strategies in order to improved performances of the Company.

2016

Memperoleh sertifikat CPOTB dari BPOM RI untuk sediaan setengah padat Resertifikasi CPOB dari BPOM RI untuk sediaan Cairan Oral Non Betalaktam dan Semi Solid Betalaktam.

Achieved CPOTB certificate from BPOM RI for semi solid dosage form, Recertification of CPOB from BPOM RI for Non-Betalactam Oral Liquid and Betalactam Semi Solid.

2018

Indofarma merubah visi, misi, *corporate value* dan identitas perusahaan, sejalan dengan cita- citanya untuk menjadi penyedia layanan healthcare terpercaya. Implementasi ERP melalui system SAP yang terintegrasi.

Indofarma changed its vision, mission, corporate value and corporate identity, in line with its aspiration of becoming a trusted healthcare provider. ERP implementation through an integrated SAP system.

2020

Perubahan nama dari PT Indofarma (Persero) Tbk menjadi PT Indofarma Tbk sehubungan dengan pengalihan saham Perseroan milik Negara Republik Indonesia ke dalam Modal PT Bio Farma (Persero).

The change of name from PT Indofarma (Persero) Tbk to PT Indofarma (Tbk) in connection with the transfer of shares of the Company owned by the Republic of Indonesia to the capital of PT Bio Farma (Persero).

2022

PT Indofarma Tbk melakukan upaya transformasi bisnis sesuai dengan penataan portofolio bisnis Holding BUMN Farmasi yaitu fokus kepada pengembangan bisnis alat kesehatan dan herbal serta meningkatkan utilisasi fasilitas produksi Farmasi dengan pengembangan bisnis toll manufaktur serta kontrak manufaktur.

PT Indofarma Tbk mulai melakukan penyerapandana PMN untuk pengembangan bisnis Alat Kesehatan dan Herbal. Pada Kuartal Terakhir 2022, PT Indofarma Tbk mempersiapkan program restrukturisasi guna penyehatan kinerja Perseroan.

PT Indofarma Tbk is carrying out business transformation efforts in accordance with the arrangement of the BUMN Pharmaceutical Holding business portfolio, namely focusing on developing the diagnostic medical equipment and herbal business as well as increasing the utilization of pharmaceutical production facilities by developing a manufacturing toll business and manufacturing contracts.

PT Indofarma Tbk began absorbing funds of PMN for the business development of the Diagnostic Medical Equipment and Herbal. In the last quarter of 2022, PT Indofarma Tbk is preparing a restructuring program to improve the Company's performance.

2021

Persetujuan kepada PT Bio Farma (Persero) untuk menugaskan/ menunjuk PT indofarma Tbk untuk melakukan importasi Vaksin COVID-19 dengan jenis dan jumlah sesuai dengan Keputusan Menteri Kesehatan Nomor HK.01.07/ Menkes/12790/2020.

Pemberian penambahan Penyertaan Modal Negara (PMN) dalam rangka perbaikan struktur permodalan serta meningkatkan kapasitas dan kapabilitas produksi alat kesehatan dan herbal Perseroan sebagai upaya percepatan kemandirian industri nasional.

Approval to PT Bio Farma (Persero) to assign/appoint PT Indofarma Tbk to import COVID-19 Vaccine with type and quantity in accordance with Minister of Health Decree Number HK.01. 07/ Menkes/12790/2020.

Provision of additional State Equity Participation (PMN) in the context of improving the capital structure as well as increasing the capacity and capability of the Company's medical equipment and herbal production as an effort to accelerate the independence of the national industry.

Produk Perusahaan

Company Products

OBAT GENERIK BERLOGO (OGB)

GENERIC DRUGS

Definisi

Obat yang telah habis masa patennya dan memiliki penamaan obat yang sama dengan zat aktif berkhasiat yang dikandungnya, sesuai dengan nama resmi International Non Proprietary Names yang telah ditetapkan dalam Farmakope Indonesia.

Jumlah Produk yang Telah Mendapatkan Nomor Izin Edar per 31 Desember 2022: 115 NIE.

Definition :

A drug with expired patent and has similar drug names with the active substance it contains, according to the official name of International Non Proprietary Names established in Farmakope Indonesia.

Number of Products Obtaining Marketing Authorization Number as of December 31, 2022: 115 NIE.

OBAT KERAS BERMEREK

ETHICAL BRANDED

Definisi

Obat generik yang diberi nama atau merek dagang.

Jumlah Produk yang Telah Mendapatkan Nomor Izin Edar per 31 Desember 2022: 83 NIE.

Definition:

A generic drug that is given a name or trademark. Number of Products Obtaining Marketing Authorization Number as of December 31, 2022: 83 NIE.



OVER THE COUNTER (OTC)

Definisi :

Obat yang dapat dibeli tanpa resep dokter, seperti obat bebas, obat bebas terbatas, obat tradisional, suplemen makanan, dan makanan.

Jumlah Produk yang Telah Mendapatkan Nomor Izin Edar per 31 Desember 2022: 38 NIE.

Definition:

A drug that can be purchased without doctor's prescription, such as over-the-counter medicines, limited over the-counter medicines, traditional medicines, food supplements, and foods.

Number of Products Obtaining Marketing Authorization Number as of December 31, 2022: 38 NIE.

ALAT KESEHATAN

MEDICAL DEVICES

Definisi :

Adalah instrumen, apparatus dan/atau implan yang tidak mengandung obat yang digunakan untuk mengidentifikasi, mencegah, dan mendiagnosis suatu penyakit atau kondisi seseorang. Alat kesehatan ini terdiri dari peralatan medis dan bahan medis habis pakai. Alat kesehatan yang telah diproduksi dan disalurkan oleh Perseroan adalah tempat tidur pasien dan kamera pendeteksi dini penyakit kanker serviks dengan merek Smart Cerviscope.

Jumlah Produk yang Telah Mendapatkan Nomor Izin Edar per 31 Desember 2022: 89 NIE.

Definition:

Instruments, apparatus and/or implants that do not contain drugs that are used to identify, prevent, diagnose a person's disease or condition. This medical device consists of medical equipment and consumables. The medical devices produced by the Company are patient beds for hospitals and health centers. The company also markets branded cancer detection cameras Smart Cerviscope.

Number of Products Obtaining Marketing Authorization Number as of December 31, 2022: 89 NIE.

PERBEKALAN KESEHATAN RUMAH TANGGA (PKRT) *HOUSEHOLD HEALTH PRODUCTS*

Definisi

Alat, bahan, atau campuran bahan untuk pemeliharaan dan perawatan kesehatan untuk manusia, pengendali kutu hewan pemeliharaan, rumah tangga, dan tempat-tempat umum. Jumlah Produk yang Telah Mendapatkan Nomor Izin Edar per 31 Desember 2022: 6 NIE.

De inition:

*Devices, materials, or material mixtures for health care and treatment of humans, animal flea control, household, and public places.
Number of Products Obtaining Marketing Authorization Number as of December 31, 2022: 6 NIE.*

NON-ALAT KESEHATAN *NON-MEDICAL DEVICES*

Definisi

*Obat generik yang diberi nama atau merek dagang.
Jumlah Produk yang Telah Mendapatkan Nomor Izin Edar per 31 Desember 2022: 83 NIE.*

Definition:

*A generic drug that is given a name or trademark.
Number of Products Obtaining Marketing Authorization Number as of December 31, 2022: 83 NIE.*



Jasa Perusahaan Company Services

Perseroan juga menyediakan jasa Toll in Manufacturing, yaitu proses produksi obat dengan menggunakan fasilitas produksi Perseroan berdasarkan permintaan produksi dari perusahaan lain.

Melalui Entitas Anak di bawah IGM, PT Farmalab Indoutama, Perseroan memberikan jasa laboratorium uji ekuivalensi BA-BE dan Disolusi Terbanding (DT) serta layanan kesehatan dan penunjang Kesehatan yang meliputi Rapid Test, Test RT-PCR Swab, dan Medical Check Up dengan kemampuan pelayanan mencakup seluruh wilayah Indonesia. Farmalab bersifat independen dan memenuhi persyaratan standar GCP dan GLP serta memenuhi ketentuan sesuai yang ditetapkan oleh WHO, Center for Drug Evaluation and Research (CDER), FDA, The European Medicines Agency (EMA), The Conduct of Bioavailability and Bioequivalence Studies (ASEAN), dan BPOM Republik Indonesia.

The Company also provides Toll Manufacturing services, where other parties produced their products using Company's production facilities based on their production demands.

Through its Subsidiary under IGM, PT Farmalab Indoutama, the Company provides laboratory services for BA-BE equivalence testing and Comparable Dissolution (DT) as well as healthcare support services including Rapid Test, RT-PCR Swab Test, and Medical Check-Up that are available in all parts of Indonesia. Farmalab is independent company and meets the requirements for the GCP and GLP standards and meets the requirements as set out by WHO, Center for Drug Evaluation and Research (CDER), FDA, The European Medicines Agency (EMA), The Conduct of Bioavailability and Bioequivalence Studies (ASEAN), and NADFC (BPOM) of the Republic of Indonesia.

Farmalab telah memiliki ruang lingkup akreditasi, mencakup:
Farmalab's scope of accreditation, consists of:

- Cefixime
- Captopril
- Omeprazole
- Diclofenac
- Sodium
- Rifampicin
- Glimepiride
- Moxifloxacin
- Gemfibrozil
- Lansoprazole



Adapun fasilitas dan layanan yang disediakan Farmalab, di antaranya:

Analisis kesehatan profesional.
Fasilitas klinik.
Fasilitas COVID-19.
Pemeriksaan & sampling.
Laboratorium Uji & Laboratorium PCR.
Alat & Instrumen Uji.
Instrumen Analisis PCR.
Mobile Lab PCR.

In the meantime, Farmalab's facilities and services, are as follow:

*Professional health analysis.
Clinic facilities.
COVID-19 facilities.
Check-up & sampling.
Test Laboratory & PCR Laboratory.
Testing Equipment and Instruments .
PCR Analysis Instruments.
PCR Mobile Lab.*

Jaringan Operasional Perusahaan Company's Operational Network

Hingga 31 Desember 2022, Perseroan memiliki 1 (satu) Kantor Pusat dan Pabrik, 1 (satu) Kantor Komersial, dan 29 (dua puluh sembilan) Kantor Cabang yang dikelola oleh Anak Perusahaan Indofarma, yaitu PT Indofarma Global Medika (IGM). Ke-29 Kantor Cabang tersebut berfungsi sebagai sarana distribusi obat dan penyaluran produk Farmasi, Obat Tradisional, dan Alat Kesehatan. Sementara, Entitas Anak kepemilikan tidak langsung PT Farmalab Indoutama memiliki 1 (satu) Laboratorium Statis BSL II.

As of December 31, 2022, The Company has 1 (one) Head Office and Factory, 1 (one) Commercial Office, and 29 (twenty-nine) Branch Offices which are managed by Indofarma's Subsidiary, namely PT Indofarma Global Medika (IGM). The 29 Branch Offices function as a means of drug distribution and distribution of Pharmaceutical products, Traditional Medicines, and Medical Devices. Meanwhile, the indirect ownership Subsidiary PT Farmalab Indoutama owns 1 (one) BSL II Static Laboratory.

Kantor Pusat dan Pabrik	Kantor Komersial	Kantor Cabang (dikelola oleh IGM)			
Head Office and Factories	Commercial Office Branch Offices	Commercial Office Branch Offices (managed by IGM)			
			Kelas 1 1st Class	Kelas 2 2nd Class	Kelas 3 3rd Class
Bekasi, Jawa Barat	Jakarta Timur, DKI Jakarta	<ol style="list-style-type: none"> 1. Jakarta 2. Bandung 3. Semarang 4. Surabaya 5. Medan 6. Makassar 	<ol style="list-style-type: none"> 1. Bekasi 2. Tangerang 3. Bogor 4. Yogyakarta 5. Purwokerto 6. Solo 7. Tegal 8. Malang 9. Palembang 10. Padang 11. Pekanbaru 12. Banjarmasin 13. Serang 	<ol style="list-style-type: none"> 1. Jember 2. Lampung 3. Banda Aceh 4. Samarinda 5. Pontianak 6. Manado 7. Denpasar 8. Kupang 9. Mataram 10. Papua 	

Profil Sumber Daya Manusia Perusahaan

Company Human Resources Profile

Hingga 31 Desember 2022, Perseroan memiliki 704 karyawan. Tabel berikut menunjukkan demografi karyawan PT Indofarma Tbk berdasarkan jenis kelamin, usia, jenjang pendidikan, level jabatan, dan status karyawan:

As of December 31, 2022, the Company has 704 employees. The following table demonstrates the demographics of the employees of PT Indofarma Tbk based on gender, age, education level, position level, and employee status:

Grafik Jumlah Karyawan dalam 5 (Lima) Tahun Terakhir


Charts of Total Employees in the Last 5 (Five) Years





Tahun Buku Fiscal Year	Jumlah Karyawan Total Employees
2018	856
2019	770
2020	748
2021	732
2022	704



Struktur Grup Perusahaan

Company's Group Structure



-  Pemegang Saham Utama dan Pengendali sekaligus Pemilik Manfaat (*Beneficial Owner*)
Majority and Controlling Shareholder as well as Beneficial Owner
-  Pemegang Saham Utama dan Pengendali
Majority and Controlling Shareholder
-  Entitas Anak (Langsung dan Tidak Langsung)
Subsidiaries (*Direct and Indirect*)
-  Entitas Asosiasi
Association Subsidiaries

Alamat dan Kontak dari Jaringan Operasional Perusahaan

Company Operational Network Addresses And Contacts

Kantor Pusat dan Pabrik *Head Office and Factories*

Jl. Indofarma No.1 Cikarang Barat, Bekasi, Jawa Barat, Indonesia – 17530
(021)-88323971/75
021)-88323972/73

Kantor Komersial *Commercial Offices*

Jl. Tambak Nomor 5, Kebon Manggis, Matraman, Jakarta Timur – 13150
(021)-2527229/30

Kantor Pusat *Head Office*

PT Indofarma Global Medika (IGM)
Kompleks Infinia Park Blok B-86, Jl. Dr. Saharjo No. 45, Jakarta Selatan, DKI Jakarta, Indonesia – 12850
(021) 83781166

Kantor Cabang (dikelola oleh IGM) *Branch Offices (managed by IGM)* **Kelas 1 / 1st Class**

Jakarta

Jl.Dr Saharjo No.45 Blok B-85, Kompleks Infinia Park, Jakarta Selatan, DKI Jakarta, Indonesia (021) 83791374/83792048/837925 | (021) 83792814

Bandung

Jl.Cibolerang No.40,Babakan Ciparay, Bandung, Jawa Barat, Indonesia (022) 54428684 | (022) 54429326

Semarang

Jl.Pamularsih Raya Kav.67 No. 60, Semarang, Jawa Tengah, Indonesia (024) 7613648-9 | (024) 7625826

Surabaya

Jl. Raya Margorego Indah Blok A-137 No.58, Surabaya, Jawa Timur, Indonesia (031) 8419377 | (031) 8435444

Medan

Kompleks Pergudangan Amplas Trade Center Blok E21-22, Jl. Sisingamaraja Km. 10.8, Medan, Sumatera Utara, Indonesia 061-88807608 | 061-88807607

Makassar

Komplek Kima 10 Kav.T-4, Biringkanaya, Makassar, Sulawesi Selatan, Indonesia (0411) 47432151 | (0411) 47432151

Kelas 2 / 2nd Class

Bekasi

I. Indofarma No. 1A, Cibitung, Bekasi, Jawa Barat, Indonesia
(021) 88323982/88329444 | (021) 88323982/88329444

Tangerang Selatan

Kompleks Pergudangan Multiguna Blok A No.5, Serpong Utara,
Tangerang Selatan, Indonesia
(021) 5399347 | (021) 5399348

Bogor

Jl. Raya Cifor No. 9, RT.01 RW.03, Bogor Barat, Kota Bogor, Jawa Barat,
Indonesia (0251) 8428660 | (021) 8428837

Yogyakarta

Jl. Garuda No. 3, Sukoharjo, Cupuwatu I RT.006 RW. 004,
Purwomartani, Kalasan, Sleman, Yogyakarta, Indonesia 0274-
487036/2850518 | 0274-484978

Medan

Kompleks Pergudangan Amplas Trade Center Blok E21-22, Jl.
Sisingamaraja Km. 10.8, Medan, Sumatera Utara, Indonesia 061-
88807608 | 061-88807607

Purwokerto

Jl. KH. Wahid Hasyim No. 16, Karang, Klesem, Purwokerto,
JawaTengah, Indonesia (0281) 627932/628462 | (0281) -635769

Solo

Jl. Slamet Riyadi No. 234, Gumpang, Kartosuro, Kabupaten Sukoharjo -
Surakarta Jawa Tengah, Indonesia
(0271) 7890207-08 | (0271) -635769

Tegal

Jl. Raya Purwahamba, RT. 009, RW. 04, Purwahamba, Suradadi, Tegal,
Jawa Tengah, Indonesia
(0283) 4531993 | (0283) 744135

Malang

Jl. Soekarno Hatta No. 80, RT. 003, RW. 006, Mojolangu, Lowokwaru,
Malang, Jawa Timur, Indonesia
(0283) 4531993 | (0283) 744135

Palembang

Jl. Ali Gathmir No.37, RT01 RW 01, Ilir Timur I, Palembang, Sumatera
Selatan, Indonesia
(0711) 351123/351323 | (0711) 321230

Padang

Jl. Bagindo Azis Chan No. 6, Padang, Sumatera Barat, Indonesia
(0751) 22034, 810347 | (0751) 25664

Pekanbaru Jl. SM Amin Arengka II No. 169 G-1, Tampan, Pekanbaru, Riau, Indonesia
(0761) 679550 | (0761) 679550

Banjarmasin Jl. Perdagangan RT. 23 Ruko No. 105 & 106, Banjarmasin Utara, Kota
Banjarmasin, Kalimantan Selatan, Indonesia
(0511) 3259359 | (0511) 3259360

Lampung Jl. Urip Sumoharjo No. 144, Gunung Sulah Way Halim, Bandar
Lampung, Lampung, Indonesia
(0721) 5602656, 5602690

Serang Jl. Raya Petir Curug No. 59, Curug, Serang, Banten, Indonesia
(0254) 8487320 | (0254) 8480321

Jember Jl. Imam Bonjol No.37, Kaliwates, Jember, Jawa Timur, Indonesia
(0331) 321832, 321833 | (0331) 489427

Lampung Jl. Urip Sumoharjo No. 144, Gunung Sulah Way Halim, Bandar
Lampung, Lampung, Indonesia
(0721) 5602656, 5602690

Banda Aceh Jl. Ir. Mohd Thaher No. 5A-5B-5C-5D, Gp. Lamdom, Lueng Bata, Banda
Aceh, DI Aceh, Indonesia
(0651) 26773. | (0651) 23199

Samarinda Jl. H. M. Kardie Oeini No. 147, Samarinda, Kalimantan Timur, Indonesia
(0541) 748572 | (0541) 748147

Pontianak Jl. Tanjung Pura No. 6, Pontianak, Kalimantan Barat, Indonesia
(0561) 765976-77 | (0561) 741208

Manado I. Ring Road I Kompleks pergudangan Ring Road Bizz Park, Blok C
No. 9, Maumbi Kec. Kelawat Kab. Minahasa, Provinsi Sulawesi Utara,
Indonesia

Denpasar Jl. Gunung Agung No. 21, Denpasar, Bali, Indonesia
(0361) 411888/416286 | (0361) 8428837

Kupang

Jl. Samratulangi V No.02, RT.020 RW.07, Kelapa Lima, Kupang, Nusa Tenggara Timur, Indonesia

Mataram

Jl. Bung Karno No. 76, Pagesangan, Mataram, Nusa Tenggara Barat, Indonesia
(0370) 626378 | (0370) 623065

Papua

Jl. Kelapa Dua Pergudangan Boulevard No. 3, Entrop, Jayapura, Papua, Indonesia
(0967) 534047/8 | (0967) 53404

Kantor Pusat dan Fasilitas

*Laboratorium
Head Office and
Laboratory Facilities*

Rumah Sakit Pendidikan UNPAD lantai 2,
Jl.Prof Eyckman No. 38, Sukajadi, Bandung. Telp:0811-9898-343





KANTOR PUSAT & PABRIK
Jl. Indofarma No. 1 Cikarang Barat, Bekasi,
Jawa Barat 17530

Phone : 021-8832 3975
Fax : 021-8832 3972/73

www.indofarma.id

   indofarma.id





PT INUKI

Highlights



PT Industri Nuklir Indonesia didirikan pada tanggal 24 Mei 1996 sebagai bagian dari bisnis pemerintah Indonesia dibidang teknologi nuklir. Perusahaan kami merupakan satu-satunya Badan Usaha milik Negara (BUMN) yang bergerak pada layanan dan produk teknologi nuklir.

PT Industri Nuklir Indonesia bertujuan untuk usaha meningkatkan pengembangan produksi radioisotop-radiofarmaka, kedokteran nuklir, produksi elemen bakar nuklir, produksi instrumentasi nuklir, dan jasa rekayasa nuklir, serta aplikasi teknologi nuklir di berbagai bidang.

PT Industri Nuklir Indonesia was established on May 24, 1996 as part of the Indonesian government's strategy for commercial utilization of nuclear technology. The company is the only state owned enterprise providing nuclear technology owned enterprise providing nuclear technology products, and services.

PT Industri Nuklir Indonesia aims to increase the development of radioisotope-radiopharmaceutical production, nuclear medicine, nuclear fuel element production, nuclear instrumentation production, and nuclear engineering services, as well as the application of nuclear technology in various fields.



Visi, Misi dan Budaya Perusahaan

Vision, Mission, and Corporate Culture

Visi

Vision

Menjadi perusahaan industri farmasi berbasis teknologi nuklir yang berdaya saing regional dan berkelanjutan.

To become a sustainable and regionally competitive nuclear-based pharmaceutical industry.

Misi

Mission

1. Meningkatkan peran iptek nuklir dalam pembangunan ketahanan nasional khususnya dibidang Kesehatan, pangan dan energi.
2. Memperkuat kapasitas dan kapabilitas bisnis sehingga produk memiliki daya saing di pasar global.
3. Memberikan manfaat dan nilai tambah kepada semua pihak yang berkepentingan dan terus-menerus.
4. Melakukan usaha produksi RI/RF, produksi EBN, dan jasa teknik yang berkualitas dengan operasi produksi yang handal, aman, dan selamat.

1. *To promote the role of nuclear technology within the development of national resilience especially in terms of healthcare, food security, and energy.*
2. *To strengthen its business capacity and capability in order to compete in global market.*
3. *To consistently contribute benefit and added value to each of its stakeholders.*
4. *To conduct business in the production of radioisotope and radiopharmaceutical, nuclear fuel element, and the procurement of technical services, with excellence in quality and reliable, safe, and secure operation.*



Sumber Daya Manusia *Human Resources*

Sumber Daya Manusia sebagai faktor pertama dan utama dalam proses pembangunan dan pencapaian tujuan perusahaan. Perusahaan menaruh perhatian terhadap pengembangan kualitas SDM melalui program dan pelatihan. Penempatan pegawai yang kompeten dan tepat pada posisinya tentu akan memberikan manfaat yang sangat baik untuk kelangsungan dan daya saing perusahaan di masa depan.

Human Resources as the first and foremost factor in the development process and the achievement of company goals. The company pays attention to the development of quality human resources through programs and trainings. The placement of competent and right employees in their positions will certainly provide excellent benefits for the survival and competitiveness of the company in the future.





Uranium
Metal Mixer

Fasilitas Produksi *Production Facilities*

PT Industri Nuklir Indonesia memiliki beberapa fasilitas produksi diantaranya hotcell, mesin-mesin fabrikasi, laboratorium kimia-fisika-biologi, dan siklotron. Hotcell adalah fasilitas yang digunakan untuk memproduksi radioisotop dari kapsul target yang telah diradiasi di Reaktor GA Siwabessy BATAN (Badan Tenaga Nuklir Nasional). Proses produksi melibatkan reaksi kimia dan fisika.

Mesin-mesin fabrikasi digunakan untuk memproduksi kapsul target radioisotop dan elemen bakar nuklir. Kaboratorium kimia-fisika-biologi digunakan untuk memeriksa produk-produk radioisotop maupun radiofarmaka.

Siklotron merupakan alat untuk produksi radioisotop F-18, C-11, O-15 dan N-13 yang digunakan pada kedokteran nuklir.

PT Industri Nuklir Indonesia have product facilities. There are hotcell, fabrication machines, chemistry-phisc-biology laboratories, and cyclotron. Hotcell is a facility that use to radioisotope production from target capsules. It was irradiated in GA Siwabessy Reactor BATAN (National Nuclear Energy Agency). Production process are chemistry and physical reactions.

Fabrication machines use to radioisotope capsule target and nuclear fuel elements production. Chemistry-phisc-Biology Laboratory use to control radioisotope and radiopharmacheutical quality products.

Cyclotron is a tool for the production of F-18, C-11, O-15 and N-13 radioisotopes used in nuclear medicine.



Uranium
Plate Cutter

Hotcell with
Manipulator Hands

Tata Kelola Perusahaan Corporate Governance



GA Siwabessy Reactor - BATAN Indonesia

Good Corporate Governace (GCG) sangat penting bagi perusahaan dikarenakan resiko dan tantangan yang dihadapi semakin meningkat. Perusahaan menerapkan prinsip keterbukaan kepada semua pihak yang berkepentingan, patuh terhadap prinsip korporasi yang sehat serta peraturan perundangan yang berlaku, dan adil dalam memenuhi kebutuhan stakeholder.


Dalam menjalankan bisnisnya, PT INUKI menjunjung tinggi dan menerapkan prinsip-prinsip GCG untuk menciptakan perusahaan yang sehat dan bersih.

Good Corporate Governance (GCG) is very important for the company because the risks and challenges faced are increasing. The company applies the principle of openness to all interested parties, complies with sound corporate principles and the applicable laws and regulations, and is fair in meeting the needs of stakeholders.

In its business, PT INUKI upholds nad applies GCG principles to create a healthy and clean company.

Elemen Bakar untuk Reaktor Nuklir

Fuel Elements for Research Reactor



Fasilitas ini di desain dengan kerjasama NUKEM GmbH - Jerman untuk memproduksi Plat tipe U, O, -Al, U, Si, -Al kedalam elemen bakar dan Elemen Reaktor Kontrol dari Uranium-235 yang diperkaya hingga 20%.

Fasilitas ini dilengkapi dengan Unit Konversi, Unit Fabrikasi, dan Unit Recovery dengan pengelasan yang berkualitas, Fraise, mesin bubut, mesin rol dingin dan panas, mesin rol otomatis, pikling, serta mesin poles.

Dengan fasilitas ini, perusahaan mampu memproduksi produk lain yang dibutuhkan untuk operasi reaktor, seperti Reflektor Beryllium, Absorber, Stringer isotop, Elemen Dummy serta batang kendali.

The facility was design under cooperation with NUKEM GmbH - Germany for producing Plate Type U, O, -Al, U, Si, -Al dispersed Fuel Element and reactor Control Elements from enriched Uranium -235 up to 20%.

For this purpose , the facility is equipped with a Cinverson Unit, Fabrication Unit, and a Scrap Recovery Unit with high quality welding, fraise, lathe, cold & hot rolling, roll swaging, pickling and polishing equipments.

With such facilities, the Company is also capable of producing other lines of products needed for reactor operation like Beryllium Reflectors, Absorber, Isotope Stringers, Dummy Elements as well as safety and control rods.

Radioisotop dan Radiofarmaka

Radioisotope and Radiopharmaceutical

Menggunakan reaktor riset sebagai 30 MW (RSG-30), berbagai radioisotop telah diproduksi untuk keperluan medis, penelitian, dan industri. Fasilitas produksi terdiri dari beberapa *hotcell* lengkap dengan manipulator *master-slave*. Fasilitas tersebut mampu menghasilkan lebih dari 20 jenis radioisotop termasuk Molybdenum-99, Iodium-131, sumber tertutup iridium-192.


Radiofarmaka diproduksi dengan teknik aseptik. Radiofarmaka yang diproduksi yaitu NAL-131 oral, NAL-131 kapsul, Nal-131 hippuran, generator technetium-99m. Radiofarmaka tersebut dapat digunakan untuk mendeteksi kerusakan pada kelenjar gondok, hati, jantung, paru-paru, dan mendeteksi tumor otak.

Untuk menjaga kualitas produk sesuai spesifikasi standar, program Jaminan Kualitas termasuk GMP (Good Manufacturing Practice) diterapkan. Ini sangat diperlukan selama semua tahapan proses termasuk pengujian bahan baku, kualifikasi personel, peralatan, kalibrasi, serta kebersihan dan sistem administrasi dokumen.

Using a 30 MW multipurpose research reactor (MPR-30), a wide variety of radioisotopes have been produced for medical, research, and industrial purposes. The production facilities are capable of producing more than 20 kinds of radioisotopes, including Molybdenum-99, Iodium-131, sealed source iridium-192.

Radiopharmaceutical are produced with an aseptic technique. Radiopharmaceutical product are Nal-131 oral solutions, Nal-131 capsules, Nal-131 hippuran, technetium-99m Generator. Radiopharmaceutical can be used to detect damage to the thyroid gland, liver, heart, lungs and detect brain tumors.

In order to secure the product quality according to standard specification, a Quality Assurance program of including GMP (Good Manufacturing Practice) is applied. This is strictly required during all stages of processing including raw material testing, personel qualification, equipment, calibration, as well as hygiene and the document administration system.



Sumber Iridium-192

Iridium-192 Source

Isotop Ir-192 digunakan untuk pengujian non-destruktif (NDT) dan pada tingkat lebih rendah sebagai radio-tracer dalam Industri Oil-gas. Radiografi gamma melibatkan pengujian dan kualitas las pada pipa bertekanan, tangki bertekanan, wadah penyimpanan berkapasitas besar, pipa, dan las struktural tertentu. bahan lain yang diuji termasuk beton (rebar atau conduit di dalam beton), bagian-bagian mesin, pelat logam, dan dinding pipa. Radiografi gamma juga digunakan untuk mengidentifikasi cacat pada pengecoran logam dan sambungan las serta untuk menunjukkan anomali struktural akibat korosi atau kerusakan mekanis.


Sumber Iridium-192 memiliki dua tipe yaitu TechOps dan GammaMat. Tipe TechOps menggunakan kamera Sentinel Delta 880, sedangkan tipe GammaMat menggunakan kamera GammaMat TS13 atau SE.

Waktu paruh Ir-192 yaitu 74 hari.

Ir-192 isotope used for non-destructive testing (NDT) and to a lesser extent as a radio-tracer in oil-gas industry. Gamma radiography involves the testing and grading of weld on pressure piping, pressure vessel, high capacity storage container, pipeline, and certain structural welds. other tested materials include concrete (locating rebar or conduit within the concrete), machine parts, plate meta, and pipe wall. Gamma radiography is also used to identify flaws in metal casting and welded joint as well as to indicate structural anomalies due to corrosion or mechanical damage.

Iridium-192 resources has two types are TechOps and GammaMat. The techOps type uses the Sentinel Delta 880 camera, while the GammaMat type uses the Gammamat TS13 or SE camera.

Half-life of ir-192 is 74 days.



Kualitas Produk

Product Quality

Inner capsule dimension	: \varnothing 5.20 mm x 0.48 mm (t) x 7.85 mm (l)
Outer capsule dimension	: \varnothing 6.35 mm x 0.48 mm (t) x 24.20 mm (l)
Ir-192 disc dimension	: \varnothing 3.00 mm x 0.12 mm thickness
Maximum disc number	: 24 pcs
Radioactivity output	: 80-100 Ci (1859-3700 GBq) per source
Total length	: 182.40 mm
Radiation energy	: 206 - 612 KeV
Radioactive dimension	: \varnothing 3.00 mm x 3.00 height
Buble leak test	: passed vacuum pressure at 20 inHg
Wipe test (ISO 2918)	: Passed at <5 mCi (<185 Bq)
Sealed number	: Double encapsulated
Sealed method	: Threaded TIG welding

Jasa Aplikasi Teknik Nuklir

Nuclear Technique Application Services

Selain melakukan bisnis dibidang nuklir dan produk sejenis, PT INUKI juga melangkah ke industri lain khususnya industri Oil-Gas, Industri Kimia dan Konstruksi dengan mendirikan kelompok produksi instrumen Nuklir, Engineering dan Aplikasi Teknik Nuklir.


Jasa teknik nuklir mencakup Uji-Tidak merusak (NDT) yaitu inspeksi radiografi menggunakan X-ray, Iridium-192, Cobalt-60, dan inspeksi non-radiografi meliputi UT-Pundit Concrete testing, Magnetic Particle testing (pendeteksi cacat bahan logam pada penerbangan, pengelasan), perangkat radio-tracing untuk pengecekan dan pendeteksian kebocoran reservoir, transportasi pasir/ endapan, dan peralatan scanning untuk proses inspeksi di industri (scanning kolom proses menggunakan neutron backscattering untuk mendeteksi cacat struktur, pengukuran laju alir deteksi penyumbatan pipa, deteksi ketebalan pipa dan korosi).

PT INUKI dilengkapi dengan bengkel mekanikal elektrik seluas 4500 m² yang mampu memproduksi berbagai komponen untuk mesin-mesin industri (turbin, heat exchanger, popa, dan vessel) dan kontrol sistem otomatis (uji ketebalan dan kekerasan material, pengukuran level, pengukuran densitas dan kelembaban).

Beside doing business in nuclear related products, Company step out in serving general industries especially Oil-Gas, Chemical and Construction by establishing Nuclear Instrument Production, Engineering and Nuclear Technique Application Group.

Service of nuclear technique cover Non-Destructive Test (NDT) such as X-ray testing, Iridium-192/Cobalt-60 radiography, UT-Pundit Concrete testing, Magnetic particle testing (metal defect detection in aircraft, welding inspection), radio-tracing equipment for reservoir leakage detection, sand/sediment transport, and scanning equipment for industrial process inspection (process coloumn scanning as well as neutron backscattering for structural defect detection, thinning/corrosion detection).

Company is equipped with a 4500-sqm modern electrical-mechanical workshop capable of produce variety of components for industrial machinery (turbine, heat exchanger, pum, vessel, and automatic system control (thickness and hardness testing, level gauging, density, and moisture probe measurement).



Kedokteran Nuklir *Nuclear Medicine*




PT Industri Nuklir Indonesia atau yang disingkat PT INUKI sejak 15 Juli 2022 telah bergabung dalam Holding BUMN Farmasi dibawah PT Bio Farma (Persero). Transformasi INUKI dari perusahaan BUMN yang hanya memproduksi radioisotop atau radiofarmaka menjadi Center of Excellence Kedokteran Nuklir melalui teknologi tinggi.

CYCLOTRON adalah alat untuk memproduksi radioisotop seperti F-18, C-14, O-15 dan N-13, F-18 adalah radioisotop yang dapat dilabel dengan FDG (Fluorodeoxyglucose) yang digunakan sebagai penelusur (tracer) pada pemeriksaan PET / CT-scan. (Positron Emission Tomography).

PT Industri Nuklir Indonesia or abbreviated as PT INUKI, since July 15, 2022 has joined the Pharmaceutical BUMN Holding under PT Bio Farma (Persero). The transformation of INUKI from a state- Owned company that only produces radioisotopes or radiopharmaceuticals becomes the Center of Excellence Nuclear Medicine through high technology.

Cyclotron is a tool for producing radioisotopes such as F-18, C-14, O-15, and N-13. F-18 is a radioisotope that can be labeled with FDG (fluorodeoxyglucose) which is used as a tracer for PET / CT-Scan examination. (Positron Emission Tomography).





International Certification Body
PT. ASIA CIPTA MANAGEMENT

Recommendation Letter

No. RC/418/II/2019/ACM-QA

Jakarta, 05 February 2019

Hereby, ACM Indonesia is pleased to state that :

PT. INDUSTRI NUKLIR INDONESIA

ISO 9001:2015

No. Certificate	:	18ACM4743 Q
Scope of work	:	"Manufacture of radioisotopes and radiopharmaceuticals including trading"
Validity	:	14 February 2021
Surveillance	:	1 (One)
Surveillance Period	:	1 Year
Audit Date	:	29 January 2019
Status	:	Continuous Recommendation

Through an audit, documented in a report, it was verified that the management system fulfills the standard requirements of the following

Sincerely Yours,
ACM Indonesia



Putu Adi
Technical Manager



Kawasan Puspipstek Serpong, Gedung 70,
Setu - Tangerang Selatan
15314, Indonesia

Phone : 021-7560211, 7560196
Fax : 021-7560118

www.inuki.co.id

    @pt_inuki



Bio Farma Group Head Office

Gd. Pakarti centre Lantai 7
Jl. Tanah Abang 3 no.23-27
Jakarta Pusat